Stock Purchase Agreement

STOCK PURCHASE AGREEMENT by and Between THORATEC CORPORATION and RADIOMETER AMERICA INC. Dated as of April 25, 2010

Exhibit 2.1
Execution Copy
by and between
THORATEC CORPORATION
and
RADIOMETER AMERICA INC.
Dated as of April 25, 2010

 


 

         
ARTICLE I. DEFINITIONS
    4  
 
       
1.1 Defined Terms
    4  
1.2 Other Defined Terms
    13  
 
       
ARTICLE II. PURCHASE AND SALE OF SHARES
    16  
 
       
2.1 Purchase Price
    16  
2.2 Purchase Price Adjustments
    16  
2.3 Earnout Amounts
    18  
 
       
ARTICLE III. CLOSING
    23  
 
       
3.1 Closing
    23  
3.2 Payment of Closing Purchase Price
    23  
3.3 Deliveries at Closing
    24  
 
       
ARTICLE IV. REPRESENTATIONS AND WARRANTIES OF SELLER
    25  
 
       
4.1 Title to Shares; Encumbrance on Assets
    25  
4.2 Seller Organization
    25  
4.3 Seller Power and Authority
    25  
4.4 Non-Contravention
    25  
4.5 Capitalization
    26  
4.6 Government Authorizations
    26  
4.7 Company Organization
    27  
4.8 No Material Adverse Effect
    27  
4.9 Financial Statements
    27  
4.10 Absence of Undisclosed Liabilities
    27  
4.11 Real Property
    28  
4.12 Labor and Employment Matters
    29  
4.13 Employee Benefit Plans
    30  
4.14 Litigation
    31  
4.15 Environmental, Health and Safety Matters
    31  
4.16 Compliance with Law
    32  
4.17 Tax Matters
    34  
4.18 Contracts
    35  
4.19 Intellectual Property
    36  
4.20 No Brokers
    38  
4.21 Absence of Changes
    38  
4.22 Unlawful Payments
    38  
4.23 Affiliate Transactions
    38  
4.24 Significant Customers and Suppliers
    39  
4.25 Insurance
    39  
4.26 Warranties; Products
    39  
4.27 Sufficiency of Assets
    40  
4.28 No Implied Representations
    40  

1


 

         
ARTICLE V. REPRESENTATIONS AND WARRANTIES OF BUYER
    40  
 
       
5.1 Organization
    40  
5.2 Authorization
    40  
5.3 Non-Contravention
    40  
5.4 Government Authorizations
    41  
5.5 Litigation
    41  
5.6 No Brokers
    41  
5.7 Financing
    41  
5.8 No Implied Representation
    41  
 
       
ARTICLE VI. COVENANTS OF SELLER AND BUYER
    41  
 
       
6.1 Further Assurances and Regulatory Approvals
    41  
6.2 Access by Buyer
    43  
6.3 Conduct of Business
    43  
6.4 Employee Matters
    47  
6.5 Confidentiality
    49  
6.6 Public Announcements
    50  
6.7 No Solicitation; Other Offers
    50  
6.8 Non-Competition; Non-Solicitation
    51  
6.9 Intercompany Arrangements
    52  
6.10 Insurance
    53  
6.11 Delivery of Updated Financial Information
    53  
6.12 Cooperation; Financial Reporting; Transition Services
    53  
6.13 Notification of Certain Matters
    54  
6.14 Title Insurance and Surveys
    55  
6.15 FDA Matters
    55  
 
       
ARTICLE VII. CONDITIONS TO SELLER’S OBLIGATIONS
    56  
 
       
7.1 Accuracy of Buyer’s Representations and Warranties
    56  
7.2 Covenants
    57  
7.3 No Laws or Governmental Orders
    57  
7.4 HSR Waiting Period
    57  
7.5 Deliveries
    57  
7.6 No Actions
    57  
7.7 Austrian Antitrust Filing
    57  
 
       
ARTICLE VIII. CONDITIONS TO BUYER’S OBLIGATIONS
    57  
 
       
8.1 Accuracy of Seller’s Representations and Warranties
    57  
8.2 Covenants
    58  
8.3 No Law or Governmental Orders
    58  
8.4 HSR Waiting Period
    58  
8.5 Deliveries
    58  
8.6 No Actions
    58  

2


 

         
8.7 Material Adverse Effect
    59  
8.8 Austrian Antitrust Filing
    59  
8.9 FDA Matters
    59  
 
       
ARTICLE IX. SURVIVAL AND INDEMNIFICATION
    59  
 
       
9.1 Survival
    59  
9.2 Indemnification
    60  
9.3 Limitations on Indemnification
    62  
 
       
ARTICLE X. TAX MATTERS
    65  
 
       
10.1 Preparation of Tax Returns
    65  
10.2 Transfer Taxes
    65  
10.3 Section 338(h)(10) Election
    66  
10.4 Cooperation; Taxes
    66  
10.5 Tax Treatment of Indemnification Payments
    66  
10.6 Tax Claims
    66  
 
       
ARTICLE XI. MISCELLANEOUS
    67  
 
       
11.1 Termination
    67  
11.2 Assignment; Successors and Assigns; No Third Party Rights
    68  
11.3 Specific Performance
    69  
11.4 Notices
    69  
11.5 Governing Law
    70  
11.6 Entire Agreement; Amendments and Waivers
    70  
11.7 Counterparts
    70  
11.8 Expenses
    71  
11.9 Severability
    71  
11.10 Titles; Gender; Certain Interpretive Matters
    71  
11.11 Disclosure Schedules; Construction of Certain Provisions
    71  
11.12 Service of Process, Consent to Jurisdiction; WAIVER OF JURY TRIAL
    72  
11.13 Independence of Agreements, Covenants, Representations and Warranties
    72  
11.14 DHR Guaranty
    73  

3


 

          THIS STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of April 25, 2010, is by and between Thoratec Corporation, a California corporation (“Seller”), and Radiometer America Inc., a Delaware corporation (“Buyer”). Seller and Buyer are each a “Party” and collectively, the “Parties”.
RECITALS
          WHEREAS, Seller is the sole record and beneficial owner of one hundred percent (100%) of the outstanding shares of common stock, no par value per share (the “Shares”), of International Technidyne Corporation (the “Company”); and
          WHEREAS, Seller wishes to sell to Buyer, and Buyer wishes to purchase from Seller, all of the Shares, upon the terms and subject to the conditions of this Agreement.
AGREEMENT
          NOW THEREFORE, in consideration of the foregoing and the respective representations, warranties, covenants and agreements of the Parties contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:
ARTICLE I.
DEFINITIONS
     1.1 Defined Terms. As used herein, the terms below shall have the following meanings. Any of such terms, unless the context otherwise requires, may be used in the singular or plural, depending upon the reference.
          “2010 Earnout Amount” means a dollar amount, if any, calculated by multiplying (a) the 2010 Gross Profit Excess by (b) 0.6.
          “2010 Gross Profit Excess” means the dollar amount by which the Gross Profit for the fiscal year ending December 31, 2010 exceeds the Gross Profit Threshold.
          “2011 Earnout Amount” means a dollar amount, if any, calculated by multiplying (a) the 2011 Gross Profit Excess by (b) 0.6.
          “2011 Gross Profit Excess” means the dollar amount by which the Gross Profit for the fiscal year ending December 31, 2011 exceeds the Gross Profit Threshold.
          “2012 Earnout Amount” means a dollar amount, if any, calculated by multiplying (a) the 2012 Gross Profit Excess by (b) 0.6.
          “2012 Gross Profit Excess” means the dollar amount by which the Gross Profit for the fiscal year ending December 31, 2012 exceeds the Gross Profit Threshold.

4


 

          “510(k) Clearance” means any and all Consents required by Section 510(k) of the FD&C Act.
          “510(k) Percentage” means (i) 100% if the Company receives 510(k) Clearance and all CLIA Waivers with respect to the InRythm products on or prior to December 31, 2010, (ii) 75% if the Company receives 510(k) Clearance and all CLIA Waivers with respect to the InRythm products after December 31, 2010 but on or prior to June 30, 2011, (iii) 50% if the Company receives 510(k) Clearance and all CLIA Waivers with respect to the InRythm products after June 30, 2011, but on or prior to December 31, 2011 and (iv) 25% if the Company receives 510(k) Clearance and all CLIA Waivers with respect to the InRythm products after December 31, 2011. Solely for purposes of determining the “510(k) Percentage,” if as of the date of consummation of a Sale Transaction the Company has not received 510(k) Clearance and all CLIA Waivers with respect to the InRythm products, then the Company shall be deemed to have received 510(k) Clearance and all CLIA Waivers on the date of consummation of such Sale Transaction.
          “Action” means any action, Claim, suit, litigation, arbitration, audit or proceeding.
          “Adjusted Net Assets” means, as of any date of determination for the Company, the sum of (a) a positive amount equal to the assets of Company and (b) a negative amount equal to the liabilities of the Company, in each case determined in accordance with GAAP (as in effect on the date of this Agreement) applied on a basis consistent with the preparation of the Company Financial Statements; provided, however, that for purposes of calculating Adjusted Net Assets, (i) assets shall not include Cash or Tax assets, (ii) liabilities shall not include any Indebtedness or Tax liabilities, except that accrued payroll tax liabilities shall be included, and (iii) neither assets nor liabilities shall include any amounts owed to, or by, the Company, on the one hand, and Seller or any Subsidiary of the Seller (other than the Company), on the other hand, all of which shall be settled prior to the Closing in accordance with the second sentence of Section 6.9 hereof.
          “Adjustment Amount” means the amount equal to the Adjusted Net Assets minus the Target Net Assets, which amount may be a positive or negative number.
          “Affiliate” has the meaning set forth in Rule 12b-2 of the regulations promulgated under the Exchange Act.
          “Agreement” means this Agreement (including the Disclosure Schedules), as the same may be amended, modified or supplemented from time to time in accordance with its terms.
          “Alternate Site Products” means the (a) ProTime® Microcoagulation System (including cuvettes and other consumables related thereto), (b) InRythm/MyRythm products (including cuvettes and other consumables related thereto), and (c) any current systems, products or platforms or future systems, products or platforms of the Company (x) that are marketed primarily for the use of prothrombin testing of blood samples by individual patients in their homes and by physicians and medical professionals in medical offices and clinics as currently planned (but not including the use of such testing in hospitals) and (y) that are substantially derived (including as to technology and Intellectual Property) from the products set forth in

5


 

clauses (a) or (b) above. All such systems described in clauses (a) and (b) above and all such current systems described in clause (c) above are set forth in Section 1.1(a) of the Seller Disclosure Schedule. For the avoidance of doubt, the Alternate Site Products do not include any products that are sold to pharmaceutical customers of the Company.
          “Assets” means all tangible, intangible and other assets, claims, rights and properties of any kind, whether accrued, contingent or otherwise, used, held for use or owned by the Company.
          “Business Day” means any day other than Saturday, Sunday or any day that is a legal holiday or a day in which banking institutions in New York are authorized by Law or other Governmental Order to close.
          “Buyer Disclosure Schedule” means the disclosure schedule delivered by Buyer to Seller on the date hereof.
          “Buyer Indemnified Parties” means Buyer and its Affiliates (including, for the avoidance of doubt, the Company) and their respective equityholders, Representatives, successors and permitted assigns (which, for the avoidance of doubt, shall not include Seller).
          “Cash” means cash, cash equivalents and short-term marketable securities of any Person, in each case (a) calculated in accordance with GAAP, (b) net of restricted balances and (c) after deducting the aggregate amount of checks outstanding but not presented for payment at such time (without duplication for any amounts to the extent included as a liability in the calculation of Adjusted Net Assets). For the avoidance of doubt, “Cash” shall not include any “auction rate” or similar securities.
          “Claim” means any claim, demand, cause of action, chose in action, right of recovery or right of set-off of whatever kind or description against any Person.
          “CLIA Waivers” means the determinations by the FDA that the ProTime InRhythm blood coagulation monitoring system of the Company is authorized for home use testing and is categorized as a waived test for home use as described in 42 U.S.C. § 263a(d)(3) and 42 C.F.R. § 493.15(b)(1) and (d).
          “Code” means the Internal Revenue Code of 1986, as amended.
          “Commercially Launch” means (a) an initial release of the applicable Alternate Site Product to a limited number of the Company’s customers for a trial period to allow such customers to use such product and to confirm whether there are any operational issues that arise from the use of such product and (b) if such initial release does not reveal any significant operational issues and any other operational issues are remedied in a reasonable fashion, a full release of the applicable Alternate Site Product to the Company’s customers and distributors.
          “Company Financial Statements” means the unaudited balance sheets of the Company as of December 29, 2007, January 3, 2009 and January 2, 2010 and the related statements of income for the fiscal years then ended.

6


 

          “Company Real Property” means, collectively, the Owned Real Property and the Leased Real Property.
          “Confidentiality Agreement” means that certain Confidential Disclosure Agreement, dated as of May 18, 2009, as amended on November 23, 2009, by and between Radiometer A/S, a wholly-owned Subsidiary of Buyer, and Seller.
          “Consents” means consents, orders, approvals, exemptions, waivers, authorizations, filings, registrations and notifications.
          “Contract” means any oral or written contract, agreement, indenture, note, bond, loan, instrument, lease, conditional sale contract, mortgage, license, franchise, commitment, undertaking or other binding arrangement.
          “controlling” means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether through the ownership of voting securities, contract or otherwise.
          “Customer Offerings” means the products that the Company (i) currently sells or licenses to third parties or (ii) has sold or licensed to third parties since January 1, 2007.
          “Disclosure Schedules” means the Buyer Disclosure Schedule and the Seller Disclosure Schedule, collectively.
          “Earnout Amounts” means, collectively, the 2010 Earnout Amount, the 2011 Earnout Amount and the 2012 Earnout Amount.
          “Earnout Period” means each of the fiscal years of the Company ended December 31, 2010, 2011 and 2012.
          “Encumbrance” means any pledge, charge, easement, security interest, mortgage, right of first refusal, option, encumbrance, lien (statutory or otherwise), preference or restriction on transfer.
          “Environmental Laws” means all Laws regulating or imposing Liabilities or standards of conduct concerning pollution or the protection of the environment, including the use, manufacture, transport, disposal or release of Hazardous Materials, Petroleum or worker health and safety (to the extent related to exposure to Hazardous Materials), together with any amendment or reauthorization thereto or thereof, as now or at any time hereafter in effect, including the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended.
          “Equity Interests” means (a) the shares of capital stock of a corporation, (b) the general or limited partnership interests of any partnership, (c) the membership or other ownership interest of any limited liability company, (d) the equity securities or other ownership interests of any kind of any other legal entity, or (e) any option, warrant or other right to convert into or otherwise receive any of the foregoing, in any such case, whether owned or held beneficially, of record or legally.

7


 

          “ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
          “Exchange Act” means the Securities Exchange Act of 1934, as amended.
          “FDA Section” means Section 4.16, other than clause (a) of such Section.
          “Fundamental Representations and Warranties” means (a) those representations and warranties contained in Section 4.1 (Title to Shares; Encumbrance on Assets), the first sentence of Section 4.2 (Seller Organization), Section 4.3 (Seller Power and Authority), Section 4.4 (Seller Non-Contravention), Section 4.5 (Capitalization), the first sentence of Section 4.7 (Company Organization), Section 4.17 (Tax Matters), Section 4.20 (No Brokers) and Section 4.23 (Affiliate Transactions), and (b) those representations and warranties contained in the first sentence of Section 5.1 (Organization), Section 5.2 (Authorization) and Section 5.4 (No Brokers).
          “GAAP” means United States generally accepted accounting principles.
          “Governmental Authority” means any court, government (federal, state, local, foreign or multinational) or other regulatory, self-regulatory, administrative, governmental or quasi-governmental agency or authority, whether foreign or domestic.
          “Governmental Authorization” means any permit, consent, license, certificate, franchise, permission, variance, clearance, registration, qualification, authorization or approval issued, granted, given or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law, including any Company Permit.
          “Governmental Order” means any judgment, decision, consent decree, injunction, ruling, writ or order of or entered by any Governmental Authority that is binding on any Person or its property under applicable Law.
          “Gross Profit” means, with respect to any fiscal year of the Company during the Earnout Period, (a) revenues from the sale of Alternate Site Products during such fiscal year minus (b) the “cost of goods sold” for Alternate Site Products for such fiscal year, in each case consistent with the principles and methodologies set forth in Section 1.1(b) of the Seller Disclosure Schedule (which such principles and methodologies are in accordance with GAAP (as in effect on the date of this Agreement) applied on a basis consistent with the preparation of the Company Financial Statements). For the avoidance of doubt, in calculating Gross Profit in any fiscal year, (i) charges for excess or obsolete inventory of the Company and (ii) expenses related to any allocation of the Purchase Price to the Alternate Site Products shall in each case not be taken into account.
          “Gross Profit Threshold” means $5,092,000.
          “Hazardous Materials” means any material, substance or waste defined, listed or regulated as “hazardous” or “toxic” (or words of similar meaning or intent) under any applicable Environmental Law, including, without limitation, materials exhibiting the characteristics of ignitability, corrosivity, reactivity or toxicity characteristic leaching procedure, as such terms are

8


 

defined in connection with hazardous materials or hazardous wastes or hazardous or toxic substances in any applicable Environmental Law, any other material, substance or waste for which Liability or standards of conduct may be imposed under any Environmental Law.
          “HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.
          “Indebtedness” shall mean at a particular time, without duplication, (a) any obligations under or for any indebtedness for borrowed money (including, without limitation, all principal, premiums, fees, expenses, indemnities and breakage costs paid to satisfy such indebtedness), whether current or funded, or secured or unsecured; (b) any indebtedness evidenced by any note, bond, debenture or other debt security; (c) obligations as lessee under any leases which are required to be capitalized in accordance with GAAP, contingently or otherwise, as obligor or guarantor; (d) obligations for deferred purchase price of property or services (excluding obligations to creditors for goods and services incurred in the original course of business); (e) amounts owed with respect to letters of credit; (f) any change of control or other amounts due to any Person to the extent incurred and payable as a result of the consummation of the transactions contemplated by this Agreement; and (g) accrued interest or penalties on any of the foregoing.
          “Intellectual Property” means the following subsisting throughout the world: (a) patents, patent applications, utility models, design registrations and certificates of invention and other governmental grants for the protection of inventions or industrial designs (including all related continuations, continuations-in-part, divisionals, reissues and reexaminations); (b) registered trademarks and service marks, logos, Internet domain names, corporate names, domain names and doing business designations and all registrations and applications for registration of the foregoing, common law trademarks and service marks and trade dress, and all goodwill in the foregoing; (c) copyrights, designs, data and database rights and registrations and applications for registration thereof, including moral rights of authors; (d) mask works and registrations and applications for registration thereof and any other rights in semiconductor topologies under the Laws of any jurisdiction; (e) inventions, invention disclosures, statutory invention registrations, trade secrets and confidential business information, know-how, manufacturing and product processes and techniques, research and development information, financial, marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and information, whether patentable or non-patentable, whether copyrightable or non-copyrightable and whether or not reduced to practice; and (f) other proprietary rights relating to any of the foregoing (including remedies against infringement thereof and rights of protection of interest therein under the Laws of all jurisdictions).
          “ISRA” means the New Jersey Industrial Site Recovery Act, N.J.S.A. 13:1K-6 et seq. and the regulations promulgated thereunder.
          “Knowledge” shall mean, in the case of (a) Seller, the actual knowledge (provided that the following individuals shall conduct reasonable inquiry in connection with any applicable matters) of Gary Burbach, David Smith, David Lehman, Larry Cohen, Jon Shear, Alex Bourdon, Diane Norton, Glen Sunnergren, Marta Chase, Greg Colella and Larry Wojcik and (b) Buyer, the actual knowledge of Christopher Korves, James Mackerer and Attila Bodi.

9


 

          “Known FDA Matters” means those matters specifically disclosed on Section 4.16(b) and Section 4.16(c) of the Seller Disclosure Schedule, other than the matters disclosed in items 6 and 8 of Section 4.16(b) of the Seller Disclosure Schedule.
          “Laws” means any laws (including common law), statutes, ordinances, regulations, rules, executive orders, and acts of any Governmental Authority.
          “Leased Real Property” means the properties set forth in Section 1.1(c) of the Seller Disclosure Schedule.
          “Liabilities” means any direct or indirect liability, Indebtedness, obligation, commitment, expense, claim, deficiency, guaranty or endorsement of or by any Person of any type, whether absolute or contingent, matured or unmatured, liquidated or unliquidated, accrued or unaccrued, asserted or unasserted, known or unknown, whenever arising, including all costs and expenses relating thereto, and including, without limitation, those liabilities, indebtedness and obligations arising under any Law, Claim, Action, threatened Action, Governmental Order or any award of any arbitrator of any kind, and those arising under any Contract.
          “Losses” means any and all costs, losses, Liabilities, obligations, damages, deficiencies and other out-of-pocket expenses, including, without limitation, interest, penalties, reasonable attorneys’ fees and reasonable costs of investigation and defense and all amounts paid in settlement of Actions relating to the foregoing, whether or not arising out of any Third Party Claims. Without limiting the generality of the foregoing, “Losses” shall also include any and all costs, losses, Liabilities, obligations, remediation costs, damages, deficiencies and other out-of-pocket expenses arising out of any injunction, settlement, seizure, criminal, civil monetary penalty or other Action taken or threatened to be taken by the FDA or any other Governmental Authority.
          “Material Adverse Effect” means any event, change, development or effect (whether or not constituting a breach of a representation, warranty, covenant or agreement set forth herein) that (a) with respect to the Company, individually or in the aggregate, has had or could reasonably be expected to have a material adverse effect on the business, operations, Assets, Liabilities, or financial condition of the Company, excluding any such effect to the extent resulting from any of the following occurring after the date of this Agreement (i) changes in general economic, industry or market conditions, in each case that do not have, and would not reasonably be expect to have, a disproportionate effect on the Company relative to other Persons in the industry in which the Company primarily operates, (ii) changes in applicable Laws, (iii) any adverse change or effect that is caused by the announcement of the transactions contemplated by this Agreement, (iv) the failure, by itself, of the Company to meet or achieve the results set forth in any internal projection (it being understood that the facts and circumstances giving rise to such failure may be taken into account to determine whether or not there has been a Material Adverse Effect), (b) with respect to Buyer, has a material and adverse effect on the ability of Buyer to consummate the transactions contemplated hereby or materially impairs the ability of Buyer to perform its obligations under this Agreement or (c) with respect to Seller, has a material and adverse effect on the ability of Seller to consummate the transactions contemplated hereby or materially impairs the ability of Seller to perform its obligations under this Agreement.

10


 

          “Neutral Arbitrator” means PricewaterhouseCoopers LLP or such other independent accounting firm of national reputation mutually appointed by Seller and Buyer.
          “ordinary course of business” or “ordinary course” or any similar phrase means the ordinary course of the business conducted by the Company, consistent with past practice.
          “Organizational Documents” means, with respect to any Person, such Person’s charter, by-laws, certificate of incorporation, limited liability company agreement, partnership agreement or other similar organizational document(s).
          “Owned Real Property” means the properties set forth in Section 1.1(d) of the Seller Disclosure Schedule.
          “Permitted Encumbrances” means (a) Encumbrances imposed by Law arising in the ordinary course of business, such as carriers’, warehousemen’s, mechanics’, materialmen’s, landlords’, laborers’, suppliers’ and vendors’ liens, and securing obligations which are not yet due or which are being contested in good faith, (b) Encumbrances for Taxes not due and payable or being contested in good faith and for which adequate reserves have been established in accordance with GAAP, (c) planning restrictions, easements, licenses, rights of way, declarations, reservations, provisions, covenants, conditions, waivers, irregularities or Encumbrances (and, with respect to leasehold interests, Encumbrances and other obligations incurred, created, assumed or permitted to exist and arising by, through or under a landlord or owner of the leased property, with or without consent of the lessee) which do not impair in any material respect the use (in the manner currently used) or value of the parcel of property to which they relate, (d) zoning, entitlement, conservation restriction and other land use and environmental regulations imposed by Governmental Authorities which do not impair in any material respect the use (in the manner currently used) or value of the parcel of property to which they relate, and (e) any extensions, renewals and replacements of an identical or lesser scope of any of the foregoing.
          “Person” means an individual, a partnership, a corporation, a limited liability company, a trust, an unincorporated organization, a Governmental Authority or any other entity.
          “Petroleum” means petroleum, including crude oil (or any fraction or blend of fractions thereof), gasoline, natural gas diesel fuel, motor oil, waste or used oil, heating oil, kerosene.
          “Pre-Closing Taxable Period” means any Tax period ending on or before the Closing Date.
          “Pre-Closing Taxes” means Taxes of the Company or for which the Company becomes liable with respect to a Tax period ending on or before the Closing Date and, in the case of a Straddle Period, the Taxes allocable pursuant to the following sentence to the portion of such Straddle Period ending on the Closing Date, in each case excluding any Taxes incurred solely by reason of any transaction effected on the Closing Date or after the Closing and any Taxes attributable to any election applicable to a Pre-Closing Taxable Period or Straddle Period filed by Buyer without Seller’s prior written consent (excluding, for the avoidance of doubt, the Section 338(h)(10) Election). The portion of any Tax that is allocable to the portion of the

11


 

Straddle Period ending on the Closing Date will be: (i) in the case of real property, personal property and similar ad valorem Taxes, deemed to be the amount of such Taxes for the entire Straddle Period multiplied by a fraction, the numerator of which is the number of calendar days of such Straddle Period up to and including the Closing Date, and the denominator of which is the number of calendar days in the entire Straddle Period, and (ii) in the case of all other Taxes, determined as though the Straddle Period terminated at the close of business on the Closing Date. Pre-Closing Taxes will not include payroll Taxes for any Straddle Period, but only if and to the extent any such payroll taxes were fully accounted for in the determination of the Final Adjustment Amount.
          “Prime Rate” means the interest rate per annum listed as the “prime rate” by JP Morgan Chase Bank, N.A. or its successor as of the date that the relevant payment should have been paid pursuant to Section 2.3.
          “Product Warranties” means all product warranties and guaranties given by the Company since January 1, 2007.
          “Purchase Price” means the Closing Purchase Price, as adjusted pursuant to Section 2.2, plus the Earnout Amounts.
          “Representative” means, with respect to any Person, any officer, director, principal, attorney, agent, employee, consultant, advisor or other authorized representative of such Person (including legal counsel, accountants, and financial advisors).
          “Sale Transaction” means (a) the sale, transfer or assignment, in one transaction or a series of related transactions of (i) all or substantially all of the assets related to the Alternate Site Products or (ii) greater than 50.1% of the Equity Interests of Buyer or the Company (or any other Subsidiary of Buyer responsible for the manufacture and sale of the Alternate Site Products), other than to an Affiliate of Buyer (provided, that any such Affiliate shall agree in writing to assume (by operation of Law, Contract or otherwise) all of the obligations of the Company pursuant to Section 2.3 as a condition to such sale); or (b) a merger or consolidation of the Company (or any other Subsidiary of Buyer responsible for the manufacture and sale of the Alternate Site Products) with or into any other entity other than an Affiliate of Buyer (provided, that any such Affiliate shall agree in writing to assume (by operation of Law, Contract or otherwise) all of the obligations of the Company pursuant to Section 2.3 as a condition to such merger or consolidation).
          “Sale Transaction Amount” means, for purposes of Section 2.3(e), as of any relevant date of determination, the amount that would be payable by Buyer to Seller pursuant to the second sentence of Section 2.3(h) if a Sale Transaction were deemed to have been consummated on such date of determination.
          “Securities Act” means the Securities Act of 1933, as amended.
          “Seller Disclosure Schedule” means the disclosure schedule delivered by Seller to Buyer on the date hereof.

12


 

          “Seller Indemnified Parties” means Seller and its Affiliates (other than the Company) and their respective equityholders, Representatives, successors and permitted assigns.
          “Specified Representations and Warranties” means those representations and warranties contained in Section 4.13 (Employee Benefit Plans), Section 4.15 (Environmental, Health and Safety Matters), Section 4.19 (Intellectual Property) and the FDA Section.
          “Straddle Period” means any Tax period beginning on or before the Closing Date and ending after the Closing Date.
          “Subsidiary” shall mean, with respect to any of the Parties, any corporation, limited liability company, partnership, association or other business entity of which (a) if a corporation, a majority of the total voting power of shares of capital stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by any such Party, or (b) if a limited liability company, partnership, association or other business entity, a majority of the partnership or other similar ownership interest thereof is at the time owned or controlled, directly or indirectly, by any such Party.
          “Target Net Assets” means $52,748,000.
          “Tax” means any federal, state, local or foreign tax, charge, duty, fee, levy or other assessment, including income, branch profits, gross receipts, license, payroll, employment, excise, escheat, severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, ad valorem, alternative or add-on minimum, estimated or other tax, or like charges of any kind whatsoever, imposed by any Governmental Authority, and including any interest, penalty or addition thereto, and including any amount owed as a result of Treasury Regulations Section 1.1502-6 or any similar provision of Law.
          “Tax Return” means any return, declaration, report, Claim for refund or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof, required to be filed with any Governmental Authority.
     1.2 Other Defined Terms. The following terms shall have the meanings defined for such terms in the Sections set forth below:
     
Term   Section
Acquired Business
  2.3(i) 
Acquired Entity
  2.3(e) 
ADSP
  10.3(b) 
Antitrust Division
  6.1(a) 
Benefit Plans
  4.13(a) 

13


 

     
Term   Section
Buyer 125 Plan
  6.4 
Buyer Plan
  4.13(a) 
Claim Notice
  9.2(c) 
Closing
  3.1 
Closing Date
  3.1 
Closing Purchase Price
  2.1 
Company Benefit Plans
  4.13(a) 
Company Intellectual Property
  4.19(b) 
Company Permits
  4.16(a) 
Company Systems
  4.19(g) 
Competing Business
  6.8(a) 
Competing Products
  2.3(e) 
Delivery Date
  2.3(b) 
DHR
  11.14(a) 
Disputed Items
  2.3(e) 
Earnout Final Settlement Date
  2.3(c) 
Earnout Notice of Disagreement
  2.3(c) 
Earnout Payoff Amount
  2.3(e) 
Earnout Statement
  2.3(b) 
Estimated Adjustment Amount
  2.1 
Estimated Closing Balance Sheet
  2.1 
Estimated Closing Cash
  2.1 
Estimated Closing Financial Certificate
  2.1 
Estimated Closing Indebtedness
  2.1 
Estimated Overall Purchase Price Adjustment
  2.1 
Excess Payment
  2.2(d)(i) 
FDA
  4.16(b) 
FDA Cost-Sharing Covenant
  6.15(b) 
FD&C Act
  4.16(b) 
Final Adjustment Amount
  2.2(a) 
Final Closing Balance Sheet
  2.2(a) 

14


 

     
Term   Section
Final Closing Cash
  2.2(a) 
Final Closing Financial Certificate
  2.2(a) 
Final Closing Indebtedness
  2.2(a) 
Final Overall Cash Purchase Price Adjustment
  2.1 
Final Settlement Date
  2.2(b) 
Guaranty
  11.14(b) 
Indemnified Claim
  9.2(d) 
Initial Cash Price
  2.1 
Insurance Policies
  4.25 
Insured Loss
  9.3(b) 
Interim Financial Information
  6.11 
NJDEP
  6.3(e) 
Non-Competition Period
  6.8(b) 
Notice of Disagreement
  2.2(b) 
Notice Period
  9.2(c) 
Preliminary Allocation
  10.3 
Regulatory Approvals
  6.1(a) 
Reimbursement Accounts
  6.4 
Restricted Party
  6.8(a) 
Retained Earnout Amount
  2.3(c) 
Sale Notice
  2.3(j) 
Section 2.3(e)(X) Notice
  2.3(e) 
Section 2.3(e)(Y) Notice
  2.3(e) 
Seller 125 Plan
  6.4 
Shortfall Reduction
  2.2(d)(i) 
Significant Customer
  4.24(a) 
Significant Supplier
  4.24(a) 
Surviving Covenants
  9.1(b) 
Tax Claims
  10.6 
Territory
  6.8(a) 
Third Party Claim
  9.2(c) 

15


 

     
Term   Section
Thoratec Financial Statements
  4.9 
Threshold Amount
  9.3(a) 
Transition Services Agreement
  6.12(b) 
ARTICLE II.
PURCHASE AND SALE OF SHARES
     2.1 Purchase Price. The Purchase Price for the Shares shall be an amount equal to (a) $110,000,000 (the “Initial Cash Price”), plus, (b) the estimated Adjustment Amount as of immediately prior to Closing (“Estimated Adjustment Amount”), which may be a positive or negative number, plus (c) the estimated Cash of the Company as of immediately prior to Closing (“Estimated Closing Cash”), which may be a positive or negative number, minus (d) the estimated Indebtedness of the Company as of immediately prior to Closing (“Estimated Closing Indebtedness”) (the amount as calculated pursuant to clauses (a)-(d), the “Closing Purchase Price”), in each case in clauses (b)-(d) as derived from the unaudited estimated balance sheet of the Company as of immediately prior to Closing (the “Estimated Closing Balance Sheet”), plus (e) the Earnout Amounts as determined pursuant to Section 2.3. The Estimated Closing Balance Sheet shall be prepared by Seller in good faith and delivered to Buyer, along with the calculation of the Estimated Adjustment Amount, Estimated Closing Cash and Estimated Closing Indebtedness, on a financial certificate (the “Estimated Closing Financial Certificate”) no later than one (1) Business Days prior to the Closing Date. The Estimated Closing Balance Sheet shall be prepared in accordance with the principles and methodologies set forth in Section 2.1 of the Seller Disclosure Schedule (which such principles and methodologies are in accordance with GAAP (as in effect on the date of this Agreement) applied on a basis consistent with the preparation of the Company Financial Statements), which shall also include illustrative calculations of the Estimated Adjustment Amount, Estimated Closing Cash and Estimated Closing Indebtedness derived therefrom. The aggregate addition or deduction to the Initial Cash Price resulting from the calculations set forth in clauses (b)-(d) shall be referred to as the “Estimated Overall Purchase Price Adjustment” and the final aggregate calculation of such amounts pursuant to Section 2.2 shall be referred to as the “Final Overall Cash Purchase Price Adjustment”.
     2.2 Purchase Price Adjustments.
          (a) Within sixty (60) days following the Closing, Buyer shall prepare and deliver to Seller a financial certificate (the “Final Closing Financial Certificate”) setting forth the unaudited balance sheet of the Company as of immediately prior to the Closing (the “Final Closing Balance Sheet”), along with the calculation of the final Adjustment Amount (“Final Adjustment Amount”), final Cash of the Company (“Final Closing Cash”) and final Indebtedness of the Company (“Final Closing Indebtedness”). The Final Closing Balance Sheet shall be prepared in accordance with the principles and methodologies set forth in Section 2.1 of the Seller Disclosure Schedule (which such principles and methodologies are in accordance with GAAP (as in effect on the date of this Agreement) applied on a basis consistent with the preparation of the Company Financial Statements), and the Final Adjustment Amount, Final

16


 

Closing Cash and Final Closing Indebtedness derived therefrom shall be prepared in accordance with the illustrative calculations thereof set forth in Section 2.1 of the Seller Disclosure Schedule. Buyer shall, in a timely manner, provide Seller such data and information as Seller may reasonably request in writing in connection with the preparation and review of the Final Closing Financial Certificate; provided, that such information right shall not include any access to documents to the extent prepared in defense of an Action concerning the Final Closing Financial Statement or the calculation of the Final Overall Cash Purchase Price Adjustment.
          (b) The Final Closing Financial Certificate shall become final and binding upon the Parties on the date (the “Final Settlement Date”) that is thirty (30) days following receipt thereof by Seller unless Seller gives written notice of its disagreement (“Notice of Disagreement”) to Buyer prior to such date; provided, that all such items that are not disputed shall be final and binding upon the Parties. In order to be effective, a Notice of Disagreement must specify in reasonable detail the dollar amount, nature and basis of any disagreement so asserted. If a Notice of Disagreement is received by Buyer in a timely manner, then the Final Closing Financial Certificate (as revised in accordance with paragraph (d) below, if applicable) shall become final and binding on the Parties on, and the Final Settlement Date shall be, the earlier of (i) the date upon which Seller and Buyer agree in writing with respect to all matters specified in the Notice of Disagreement and (ii) the date upon which the Final Closing Financial Certificate is issued by the Neutral Arbitrator.
          (c) During the first twenty (20) days following the date upon which Buyer receives a Notice of Disagreement, Seller and Buyer shall attempt in good faith to resolve in writing any differences that they may have with respect to all matters specified in the Notice of Disagreement. If at the end of such twenty (20) day period (or earlier by mutual agreement to arbitrate) Buyer and Seller have not reached agreement on such matters, the matters that remain in dispute shall be submitted to the Neutral Arbitrator by the Parties for review and resolution. The terms of appointment and engagement of the Neutral Arbitrator shall be as agreed upon in good faith between the Parties and any associated engagement fees shall initially be borne 50% by Seller and 50% by Buyer; provided, that such fees shall ultimately be allocated in accordance with the fee sharing provisions set forth below in this Section 2.2(c). The hearing date will be scheduled by the Neutral Arbitrator as soon as reasonably practicable, and shall be conducted on a confidential basis. Each Party shall, not later than seven (7) days prior to the hearing date set by the Neutral Arbitrator, submit a brief (to include such Party’s calculations with regard to amounts in dispute on the Closing Statement) for settlement of any amounts set forth in the Notice of Disagreement that remain in dispute. The Neutral Arbitrator shall render a decision resolving the matters in dispute on the basis of the standards set forth in this Section 2.2 (which decision shall include a written statement of findings and conclusions) within ten (10) Business Days after the conclusion of the hearing, unless the Parties reach agreement prior thereto and withdraw the dispute from arbitration; provided, that the Neutral Arbitrator shall not assign a value to any disputed item greater than the greatest value for such item assigned to it by Buyer or Seller, as the case may be, or less than the smallest value for such item assigned to it by Buyer or Seller, as the case may be. The Neutral Arbitrator shall provide to the Parties explanations in writing of the reasons for its decisions regarding the Final Adjustment Amount, Final Closing Cash and Final Closing Indebtedness and shall issue the Final Closing Financial Certificate reflecting such decisions. The decision of the Neutral Arbitrator shall be final and binding on the Parties. If the Neutral Arbitrator resolves all disputes presented to it entirely in

17


 

the manner proposed by either Seller or Buyer, as the case may be, the fees and expenses of the Neutral Arbitrator shall be borne by the non-prevailing Party. In all other events, the fees and expenses of the Neutral Arbitrator shall be shared based on the difference between Seller’s position, on the one hand, and Buyer’s position, on the other hand, initially presented to the Neutral Arbitrator (based on the aggregate of all differences taken as a whole) and the final resolution as determined by the Neutral Arbitrator in proportion to the total difference between Seller’s and Buyer’s initial positions. The fees and disbursements of Buyer’s independent public accountants incurred in connection with the procedures performed with respect to the Final Closing Financial Certificate shall be borne by Buyer and the fees and disbursements of Seller’s independent public accountants incurred in connection with their preparation of the Notice of Disagreement shall be borne by Seller.
          (d) (i) If the Final Overall Cash Purchase Price Adjustment as derived from the Final Closing Financial Certificate is less than the Estimated Overall Cash Purchase Price Adjustment, the Closing Purchase Price shall be decreased by an amount equal to such excess of the Estimated Overall Cash Purchase Price Adjustment over the Final Overall Cash Purchase Price Adjustment as derived from the Final Closing Financial Certificate (“Shortfall Reduction”) and (ii) if the Final Overall Cash Purchase Price Adjustment as derived from the Final Closing Financial Certificate is greater than the Estimated Overall Cash Purchase Price Adjustment, the Closing Purchase Price shall be increased by an amount equal to such excess of the Final Overall Cash Purchase Price Adjustment as derived from the Final Closing Financial Certificate over the Estimated Overall Cash Purchase Price Adjustment (“Excess Payment”).
          (e) Any Shortfall Reduction or Excess Payment described in clause (i) or (ii) in Section 2.2(d) shall be paid to Buyer or Seller, as the case may be, not later than three (3) Business Days after the Final Settlement Date by wire transfer of immediately available funds to an account or accounts specified by Buyer or Seller, as applicable, and shall be considered an adjustment to the Closing Purchase Price. The amount of any Shortfall Reduction or Excess Payment to be made after the Closing Date pursuant to this Section 2.2(e) shall bear interest from and including the Closing Date to but excluding the date of payment to Buyer or Seller, as the case may be, at a rate per annum equal to the prime rate as published in the Wall Street Journal, Eastern Edition, in effect on the Closing Date. Such interest shall be payable at the same time as the payment to which it relates and shall be calculated daily on the basis of a year of 365 days and the actual number of days elapsed.
     2.3 Earnout Amounts.
          (a) As additional consideration for the Shares, Seller shall be entitled, subject to the terms and conditions of this Section 2.3, to the Earnout Amounts.
          (b) Buyer shall deliver to Seller within forty-five (45) days of the end of each of the fiscal years included in the Earnout Period (each such date of delivery, a “Delivery Date”): (i) a worksheet setting forth, in reasonable detail, the calculation of the 2010 Earnout Amount, 2011 Earnout Amount or 2012 Earnout Amount, as applicable, including all necessary back-up calculations, each such worksheet to use the methodology used in determining the Gross Profit Threshold as set forth in Section 1.1(b) of the Seller Disclosure Schedule (each such statement, an “Earnout Statement”); and (ii) the 2010 Earnout Amount, the 2011 Earnout

18


 

Amount or the 2012 Earnout Amount, as applicable, set forth on the Earnout Statement by wire transfer of immediately available funds to a bank account in the United States designated by Seller in writing. Buyer shall provide Seller such data and information as Seller may reasonably request in connection with the preparation and review of each Earnout Statement.
          (c) The applicable Earnout Statement shall become final and binding upon the Parties on the date (the “Earnout Final Settlement Date”) that is thirty (30) days following receipt thereof by Seller unless Seller gives written notice of its disagreement (“Earnout Notice of Disagreement”) to Buyer prior to such date; provided, that all such items that are not disputed shall be final and binding upon the Parties; provided further, that Seller may retain the 2010 Earnout Amount, the 2011 Earnout Amount or the 2012 Earnout Amount, as applicable, delivered by Buyer in connection with the applicable Earnout Statement in the event it delivers an Earnout Notice of Disagreement (the “Retained Earnout Amount”). In order to be effective, an Earnout Notice of Disagreement must specify in reasonable detail the dollar amount, nature and basis of any disagreement so asserted. If an Earnout Notice of Disagreement is received by Buyer in a timely manner, then the applicable Earnout Statement (as revised in accordance with paragraph (d) below, if applicable) shall become final and binding on the Parties on, and the Earnout Final Settlement Date shall be, the earlier of (i) the date upon which Seller and Buyer agree in writing with respect to all matters specified in the Earnout Notice of Disagreement and (ii) the date upon which the final applicable Earnout Statement is issued by the Neutral Arbitrator.
          (d) During the first twenty (20) days following the date upon which Buyer receives an Earnout Notice of Disagreement, Seller and Buyer shall attempt in good faith to resolve in writing any differences that they may have with respect to all matters specified in the Earnout Notice of Disagreement. If at the end of such twenty (20) day period (or earlier by mutual agreement to arbitrate) Buyer and Seller have not reached agreement on such matters, the matters that remain in dispute shall be submitted to the Neutral Arbitrator by the Parties for review and resolution. The terms of appointment and engagement of the Neutral Arbitrator shall be as agreed upon in good faith between the Parties and any associated engagement fees shall initially be borne 50% by Seller and 50% by Buyer; provided, that such fees shall ultimately be allocated in accordance with the fee sharing provisions set forth below in this Section 2.3(d). The hearing date will be scheduled by the Neutral Arbitrator as soon as reasonably practicable, and shall be conducted on a confidential basis. Each Party shall, not later than seven (7) days prior to the hearing date set by the Neutral Arbitrator, submit a brief (to include such Party’s calculations with regard to amounts in dispute on the Earnout Statement) for settlement of any amounts set forth in the Earnout Notice of Disagreement that remain in dispute. The Neutral Arbitrator shall render a decision resolving the matters in dispute on the basis of the standards set forth in this Section 2.3 (which decision shall include a written statement of findings and conclusions) within ten (10) Business Days after the conclusion of the hearing, unless the Parties reach agreement prior thereto and withdraw the dispute from arbitration; provided, that the Neutral Arbitrator shall not assign a value to any disputed item greater than the greatest value for such item assigned to it by Buyer or Seller, as the case may be, or less than the smallest value for such item assigned to it by Buyer or Seller, as the case may be. The Neutral Arbitrator shall provide to the Parties explanations in writing of the reasons for its decisions regarding the Earnout Statement and shall issue a final Earnout Statement reflecting such decisions. The decision of the Neutral Arbitrator shall be final and

19


 

binding on the Parties. If the Neutral Arbitrator resolves all disputes presented to it entirely in the manner proposed by either Seller or Buyer, as the case may be, the fees and expenses of the Neutral Arbitrator shall be borne by the non-prevailing Party. In all other events, the fees and expenses of the Neutral Arbitrator shall be shared based on the difference between Seller’s position, on the one hand, and Buyer’s position, on the other hand, initially presented to the Neutral Arbitrator (based on the aggregate of all differences taken as a whole) and the final resolution as determined by the Neutral Arbitrator in proportion to the total difference between Seller’s and Buyer’s initial positions. Buyer shall pay the 2010 Earnout Amount, the 2011 Earnout Amount or the 2012 Earnout Amount, as applicable and as finally determined, if any, less the Retained Earnout Amount, to Seller within five business days after Seller’s acceptance of, or the final resolution of, such amount, plus interest thereon from the applicable Delivery Date at a rate per annum equal to the prime rate as published in the Wall Street Journal, Eastern Edition, in effect on the Closing Date. Such interest shall be payable at the same time as the payment to which it relates and shall be calculated daily on the basis of a year of 365 days and the actual number of days elapsed. Any Earnout Amounts paid by Buyer pursuant to this Section 2.3 shall be considered adjustments to the Purchase Price.
          (e) Buyer agrees and covenants, for itself, its Subsidiaries and any other Person in which it holds, directly or indirectly, controlling Equity Interests, that during the period from the Closing Date until the conclusion of the Earnout Period, (i) Buyer will operate the Company in good faith and, subject to Buyer’s reasonable commercial judgment, will not take any action that would reasonably be expected to reduce Gross Profits, (ii) Buyer shall use commercially reasonable efforts not to (A) engage in activities or transactions that would reasonably be expected to defer the receipt or recognition of revenue or accelerate the payment or recognition of expenses taken into account in calculating the Earnout Amounts, or (B) take any actions that would reasonably be expected to reduce the sales of any Alternate Site Products, (iii) Buyer shall not, and shall not permit any of its Subsidiaries to, directly or indirectly, transfer or sell any of the Alternate Site Products to any Affiliate of Buyer (or any third Person) during the Earnout Period unless the terms and conditions related to such transaction are at least as favorable to the Company as those which could be obtained in an arms’-length transaction, (iv) Buyer shall use commercially reasonable efforts to obtain any regulatory approvals required in respect of Alternate Site Products and to Commercially Launch such Alternate Site Products promptly upon receipt of such regulatory approvals, (v) Buyer shall use commercially reasonable efforts not to take any actions with respect to the manner or location of the manufacture or production of the Alternate Site Products which would reasonably be expected to increase the costs of such manufacture or production, (vi) Buyer shall use commercially reasonable efforts to continue ongoing discussions with the parties set forth on Section 2.3(e) of the Seller Disclosure Schedule for the distribution of InRythm and MyRythm products and shall designate at least $200,000 in the aggregate to promote the Alternate Site Products, (vii) Buyer shall designate at least $150,000 in the aggregate for the marketing of MyRythm products in connection with Commercially Launching such products, and (viii) Buyer shall increase the number of dedicated salespeople for the Alternate Site Products by one (1) following the Company’s receipt of 510(k) Clearance with respect to the InRythm products, by an additional two (2) following the Company’s receipt of 510(k) Clearance with respect to the MyRythm products and by an additional two (2) following the Company’s receipt of all CLIA Waivers with respect to the InRythm and MyRythm products. During the period from the Closing Date until the conclusion of the Earnout Period, neither

20


 

Buyer nor any of its Subsidiaries shall market any products that directly compete with the Alternate Site Products in the Territory (the “Competing Products”). For the avoidance of doubt, neither Buyer nor any of its Subsidiaries shall be restricted by the provisions of this Section 2.3(e) from selling or marketing the AQT 90 product (or any future systems, products or platforms similar to the AQT 90 Product) or any other multi-test platform product that includes prothrombin testing among other testing parameters. Notwithstanding anything to the contrary contained in this Section 2.3(e), neither Buyer nor any of its Subsidiaries shall be prohibited from acquiring (whether through a purchase of stock or assets, through a merger or consolidation, or otherwise) any Person (each, an “Acquired Entity”) so long as: (X) if such Acquired Entity sells Competing Products and such Acquired Entity derives ten million dollars or less of gross revenues (as measured from the conclusion of such Acquired Entity’s last completed fiscal year) from the sale of such Competing Products, Buyer shall provide written notice to Seller of such fact (the “Section 2.3(e)(X) Notice”) and Buyer shall take one (and only one) of the following actions (as determined by Buyer in its sole discretion): (i) divest, as soon as reasonably practicable (but in any event within twelve months of Seller’s receipt of the Section 2.3(e)(X) Notice), the business of such Acquired Entity that engages in the sale of Competing Products and hold such business “Separate” from the Company during the period prior to such divestiture, (ii) elect to pay to Seller an amount that represents the expected Earnout Amount required to be paid by Buyer to Seller under this Section 2.3 for the remaining portion of the Earnout Period as of the time of Buyer’s election (the “Earnout Payoff Amount”), as mutually agreed between Buyer and Seller at the time of such election (or, if applicable, as determined by the Neutral Arbitrator) or (iii) operate the business of such Person that engages in the sale of Competing Products “Separate” from the Company, which, for purposes of this Section 2.3(e), shall be defined as (a) operating such business as an entity that has a separate legal existence from the Company, (b) taking all reasonable steps to ensure that all Confidential Information of the Company is not shared with, or otherwise disclosed to, any employees of such business, (c) employing an operating team to manage such business that is separate from the Company’s operating team, (d) prohibiting employees of the Company from working for, or otherwise providing services to, such business, and (e) prohibiting employees of such business from working for, or otherwise providing services to, the Company; or (Y) if such Acquired Entity sells Competing Products and such Acquired Entity derives more than ten million dollars of gross revenues (as measured from the conclusion of such Acquired Entity’s last completed fiscal year) from the sale of such Competing Products, Buyer shall provide written notice to Seller of such fact (the “Section 2.3(e)(Y) Notice”) and Buyer shall, at its sole option, either (i) divest, as soon as reasonably practicable (but in any event within twelve months of Seller’s receipt of the Section 2.3(e)(Y) Notice), the business of such Acquired Entity that engages in the sale of Competing Products and hold such business “Separate” from the Company during the period prior to such divestiture or (ii) elect to pay to Seller the Earnout Payoff Amount, as mutually agreed between Buyer and Seller at the time of such election (or, if applicable, as determined by the Neutral Arbitrator). If Buyer and Seller are unable to reach agreement on the Earnout Payoff Amount (such items in dispute being herein referred to as the “Disputed Items”), the Disputed Items shall be submitted to the Neutral Arbitrator within 30 days of Seller’s receipt of the Section 2.3(e)(X) Notice or the Section 2.3(e)(Y) Notice (as applicable) and the dispute procedures set forth in Section 2.3(d) above shall govern the Parties’ respective rights and obligations with respect to resolving such Disputed Items. In no event shall the Earnout Payoff Amount exceed the applicable Sale Transaction Amount. Upon the payment of

21


 

the Earnout Payoff Amount in full, no Party shall have any further obligations or liabilities pursuant to this Section 2.3. Notwithstanding anything to the contrary contained in Section 2.3(e): (I) Buyer’s obligation to use “commercially reasonable efforts” in complying with this Section 2.3(e) shall not require Buyer to continue to sell an Alternate Site Product if there is any product recall or product discontinuation implemented by the Company with respect to such Alternate Site Product; provided, that such recall or discontinuation (a) is required by any actual or proposed (in writing) injunction, judgment, decree, order or other Action of any Government Authority or (b) is effected in response to or settlement of (i) any actual or proposed (in writing) Action, fine, penalty, sanction, or other adverse consequence imposed by any Government Authority with respect to such Alternate Site Product or (ii) a good faith determination by the Company that such Alternate Site Product does not provide the results intended by its design to an extent that the Company determines that such Alternate Site Product, unless recalled or discontinued, may substantially compromise patient safety; and (II) Buyer shall only be obligated to develop, market and sell any Alternate Site Product to the extent permitted by applicable Law, the FDA and any other Governmental Authorities.
          (f) Buyer shall allow an independent accounting firm selected by Seller, not more than once during any fiscal year during the Earnout Period (and for 180 days following the conclusion of the Earnout Period) and only upon prior written notice to Buyer, to inspect, at Seller’s sole cost and expense, Buyer’s books, records, agreements and other documents reasonably requested by Seller relating to the Alternate Site Products in order to ensure Buyer’s compliance with the provisions of this Section 2.3. Notwithstanding anything to the contrary in this Agreement, (i) Buyer shall not be required to take any action pursuant to this Section 2.3(f) which could reasonably be expected to result in a waiver of the attorney-client privilege, and (ii) Buyer need not supply Seller with any access or information which Buyer or any of its Affiliates is under a legal obligation not to supply. Buyer shall also provide Seller, within forty-five (45) days of the end of each of the first, second and third fiscal quarters of each fiscal year of the Earnout Period, a non-binding calculation of the Gross Profit for such quarter, determined in accordance with the methodology set forth in Section 1.1(b) of the Seller Disclosure Schedule; provided, that the failure by Seller to contest or respond to such calculation of Gross Profit shall in no way affect or prejudice any of Seller’s rights pursuant to this Section 2.3.
          (g) Nothing in this Agreement shall be interpreted as a restriction or limitation on the Company and its Affiliates’ right and ability to acquire by purchase, exchange, or otherwise, any other Person, whether or not engaged in a business similar or related to the business of the Company, subject to the terms and conditions set forth in Section 2.3(e) governing the acquisition of an Acquired Entity.
          (h) In the event that a Sale Transaction occurs prior to the conclusion of the Earnout Period, Buyer shall, no later than ten (10) Business Days prior to the anticipated date of the consummation of such Sale Transaction, deliver written notice of such Sale Transaction to Seller (such notice, the “Sale Notice”). On the date of the consummation of such Sale Transaction, Buyer shall pay to Seller: (i) $25,688,000 if such Sale Transaction occurs during the 2010 Earnout Period; (ii) $24,411,000 (plus all of the 2010 Earnout Amounts, if any, due and not yet paid to Seller) multiplied by the 510(k) Percentage if such Sale Transaction occurs during the 2011 Earnout Period; and (iii) $14,648,000 (plus all of the 2010 Earnout Amounts

22


 

and the 2011 Earnout Amounts, in each case if any, due and not yet paid to Seller at time of the consummation of such Sale Transaction) multiplied by the 510(k) Percentage if such Sale Transaction occurs during the 2012 Earnout Period. Upon the payment by Buyer of the applicable amount to Seller in accordance with the preceding sentence, no Party shall have any further obligations or liabilities pursuant to this Section 2.3. In the event of any sale of a material portion of the assets of the Company related to the product line for the Alternate Site Products in a transaction that does not qualify as a Sale Transaction, Buyer shall cause the purchaser in such transaction to assume (whether by operation of Law or otherwise) the relevant portion of the obligations of Buyer set forth in this Section 2.3 and the Gross Profits attributable to sales of Alternate Site Products by such purchaser shall be included in the calculation of Gross Profits for purposes of determining the Earnout Amounts.
          (i) Buyer has the right to set-off any amounts owed by Seller to any Buyer Indemnified Party pursuant to Article IX against any amount payable to Seller pursuant to this Section 2.3. To the extent any amounts set-off pursuant to the preceding sentence are finally determined pursuant to Article IX to not be owed by Seller to such Buyer Indemnified Party, Buyer shall promptly pay Seller such amounts, including interest accruing thereon from the original due date of such payment to the date of payment at a rate equal to the Prime Rate.
          (j) Buyer shall have the right to withhold amounts for Taxes as required by Law from any payments made to Seller pursuant to this Section 2.3 if Seller has failed to provide Buyer with an appropriate certificate or document prescribed by the United States Internal Revenue Service certifying Seller’s entitlement to, exemption from, or reduction in the rate of, withholding for Taxes. Buyer shall not be required to gross-up any such payment to Seller as a result of any withholding pursuant to this Section 2.3(j).
ARTICLE III.
CLOSING
     3.1 Closing . Unless this Agreement shall have been terminated in accordance with Section 11.1 hereof, the closing of the purchase and sale of the Shares (the “Closing”) shall be held at 10:00 a.m. New York time at the offices of Latham & Watkins LLP, at 885 Third Avenue, New York, NY 10022, on the fourth (4th) Business Day following the satisfaction or waiver of all of the conditions precedent to the obligations of the Parties set forth in Articles VII and VIII (other than conditions which are not capable of being satisfied until the Closing Date, but subject to satisfaction and waiver thereof at the Closing) (the “Closing Date”), unless the Parties hereto otherwise agree in writing.
     3.2 Payment of Closing Purchase Price. Upon the terms and subject to the satisfaction or waiver of the conditions contained in this Agreement, in consideration of the aforesaid sale, conveyance, transfer, assignment and delivery of the Shares, Buyer will pay Seller at the Closing the Closing Purchase Price, by wire transfer of immediately available funds to an account designated in writing by Seller.

23


 

     3.3 Deliveries at Closing.
          (a) To effect the transactions contemplated hereby, Seller shall, at the Closing, deliver to Buyer, or cause to be delivered to Buyer (unless previously delivered):
          (i) a stock certificate, duly endorsed by Seller for transfer to Buyer, representing the Shares and any other documents necessary to transfer to Buyer good and marketable title to the Shares free and clear of all Liens (other than restrictions under applicable securities Laws);
          (ii) the letters of resignation of the members of the board of directors of the Company;
          (iii) an affidavit of Seller, dated as of the Closing Date and substantially in the form set forth in Treasury Regulations Section 1.1445-2(b), certifying Seller’s non-foreign status;
          (iv) the certificates and other documents required to be delivered at Closing as described in Article VIII;
          (v) a release and waiver from Seller and its Subsidiaries (other than the Company), with respect to pre-Closing matters involving the Company;
          (vi) a certificate executed by the Secretary of the Company certifying that attached thereto are (A) a true, complete and correct copy of the certificate of incorporation of the Company, as in effect on the Closing Date, certified by an appropriate authority of the State of Delaware, (B) a true, complete and correct copy of the by-laws of the Company, as in effect on the Closing Date, (C) true, complete and correct copies of resolutions of the Company’s Board of Directors and the sole stockholder, respectively, authorizing the execution, delivery and performance of this Agreement and the transactions contemplated hereby, which resolutions have not been modified, rescinded or revoked, and (D) specimen signatures of the officers of the Company authorized to sign this Agreement and the other documents delivered by Seller pursuant to this Agreement;
          (vii) with respect to Seller, a certificate issued by an appropriate authority of the State of California, certifying as of a date no more than five (5) days prior to the Closing Date that Seller is in good standing under the Laws of the State of California;
          (viii) with respect to the Company, a certificate issued by the Secretary of State of the State of Delaware and each other jurisdiction in which the Company is qualified to do business, certifying as of a date no more than five (5) days prior to the Closing Date that the Company is in good standing under the Laws of such jurisdictions; and
          (ix) all such other documents, certificates and instruments as Buyer may reasonably request in order to give effect to the transactions contemplated hereby.

24


 

          (b) To effect the transactions contemplated hereby, Buyer shall, at the Closing, deliver to Seller, or cause to be delivered to Seller (unless previously delivered):
          (i) an amount equal to the Closing Purchase Price, payable in accordance with Section 3.2 hereof; and
          (ii) the certificates and other documents required to be delivered at the Closing as described in Article VII.
          (c) Each such document contemplated by this Section 3.3 shall be in form and substance, and shall be executed and delivered in a manner, reasonably satisfactory to the Parties.
ARTICLE IV.
REPRESENTATIONS AND WARRANTIES OF SELLER
          Seller hereby represents and warrants to Buyer as follows:
     4.1 Title to Shares; Encumbrance on Assets. Seller owns all of the Shares beneficially and of record, free and clear of any Encumbrance and, upon delivery of and payment for such Shares at the Closing as herein provided, Seller will convey to Buyer good and valid title thereto, free and clear of any Encumbrance. Except as set forth on Section 4.1 of the Seller Disclosure Schedule, the Company owns all of its Assets free and clear of any Encumbrance (other than Permitted Encumbrances).
     4.2 Seller Organization. Seller is a corporation duly organized, validly existing and in good standing under the laws of the State of California, with the requisite corporate power and authority to conduct its business as it is presently being conducted. Seller is duly qualified or licensed to do business in each jurisdiction in which the property owned, leased or operated by Seller or the nature of the business conducted by Seller makes such qualification necessary, except in any such jurisdictions where the failure to be duly so qualified or licensed would not have a Material Adverse Effect on Seller.
     4.3 Seller Power and Authority. Seller has all requisite corporate power and authority and has taken all corporate action necessary, to execute and deliver this Agreement and the other agreements contemplated hereby, to consummate the transactions contemplated hereby and thereby, and to perform its obligations hereunder and thereunder. This Agreement and the other agreements contemplated hereby have been duly executed and delivered by Seller and, assuming the due authorization, execution and delivery of this Agreement and such other agreements by Buyer, are legal, valid and binding obligations of Seller, enforceable against Seller in accordance with their respective terms, except as may be limited by the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating to or affecting creditors’ rights generally and general equitable principles (whether considered in a proceeding in equity or at law).
     4.4 Non-Contravention. Except as set forth on Section 4.4 of the Seller Disclosure Schedule, neither the execution and delivery of this Agreement or the other agreements contemplated hereby by Seller, nor the consummation of the transactions contemplated hereby or

25


 

thereby will (a) conflict with or result in a breach or violation of any provision of the Organizational Documents of Seller or the Company or, to the Knowledge of Seller, any resolution of the board of directors of Seller or the Company; (b) violate or result in a default or breach of (or an event that with notice or lapse of time or both would become a default or breach) or give rise to any right of termination, modification, Consent or acceleration under, or result in the loss of any material right or the imposition of any Liability under, any material Contract of Seller or a Material Contract of the Company; (c) violate any Law or any Governmental Order applicable to Seller or the Company; (d) result in the creation of any Encumbrance on the Shares or any material Asset; or (e) result in a default under or a breach or violation of, or adversely affects the rights and benefits afforded to the Company by, any Company Permit.
     4.5 Capitalization.
          (a) The authorized equity capitalization of the Company consists of one hundred (100) shares of common stock, of which one hundred (100) shares are issued and outstanding. The Shares are duly authorized, validly issued, fully paid and non-assessable and were not issued in violation of, and are not currently subject to, any preemptive right, right of first refusal or other similar rights. The Company has no other shares of capital stock or other Equity Interests issued or outstanding.
          (b) Seller has good and valid title to the Shares, with the full legal right, authority and power to sell, transfer and convey the Shares to Buyer in accordance with the terms of this Agreement.
          (c) All of the Shares were offered, issued, sold and delivered by the Company in compliance with all applicable Laws governing the issuance of securities. There are no outstanding or authorized equity appreciation, phantom equity or similar rights with respect to the Company. Neither Seller nor the Company is party to any Contract with a third party with respect to the voting, sale, transfer or purchase of the Shares and no Person has any outstanding or authorized option, warrant, right, call, commitment, subscription right, conversion right, exchange right, preemptive right or other securities or agreements (written or oral, firm and conditional) or any right or privilege capable of becoming an option, warrant, right, call, commitment, subscription right, conversion right, exchange right, preemptive right or other security or agreement pursuant to which (i) Seller or the Company is or may become obligated to issue, sell, transfer or otherwise dispose of, redeem or acquire any of the Shares, or any interest in the share capital of the Company or (ii) the Company has granted, or may be obligated to grant, to any Person (other than a registered holder of Shares and in respect of such Shares only), a right to participate in the profits of the Company.
          (d) The Company has no Subsidiaries. The Company does not own any Equity Interest, or any interest convertible or exchangeable into an Equity Interest, in any Person.
     4.6 Government Authorizations. Except for any filings and Consents required under the HSR Act, no Consent of, with or to any Governmental Authority is required to be obtained or

26


 

made by the Company, Seller or Seller’s Subsidiaries in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby.
     4.7 Company Organization. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, with the requisite corporate power and authority to conduct its business as it is presently being conducted. The Company is duly qualified or licensed to do business in each jurisdiction in which the property owned, leased or operated by the Company or the nature of the business conducted by the Company makes such qualification necessary (which jurisdictions are listed on Section 4.7 of the Seller Disclosure Schedule), except in any such jurisdictions where the failure to be duly so qualified or licensed would not have a Material Adverse Effect on the Company.
     4.8 No Material Adverse Effect. Since January 2, 2010 and through the date hereof, there has not been a Material Adverse Effect on the Company.
     4.9 Financial Statements.
          (a) Subject to the limitations with respect thereto as set forth in the succeeding provisions of this Section 4.9(a), true and complete copies of the Company Financial Statements are set forth on Section 4.9(a) of the Seller Disclosure Schedule. The Company Financial Statements (i) have been prepared from the books and records of the Company on a consistent basis through the periods covered thereby, (ii) have been prepared in accordance with GAAP applied on a consistent basis through the periods covered thereby (except (A) as set forth in the explanatory footnotes thereto, (B) with respect to the treatment of stock-based compensation expense therein and (C) with respect to the treatment of federal and state income Taxes) and (iii) fairly present, in all material respects, the financial position and results of operations of the Company as of their respective dates. Each of the audited balance sheets of Thoratec Corporation as of December 29, 2007, January 3, 2009 and January 2, 2010 and the related statements of income for the fiscal years then ended (collectively, the “Thoratec Financial Statements”) contain the relevant Company Financial Statements for the time periods applicable thereto. The Thoratec Financial Statements have been prepared in accordance with GAAP applied on a consistent basis through the periods covered thereby and fairly present, in all material respects, the financial position and results of operations of Seller as of their respective dates. Section 4.9(a) of the Seller Disclosure Schedule contains a complete list of all Indebtedness of the Company and identifies for each item of Indebtedness the outstanding principal and accrued but unpaid interest as of the date of this Agreement.
          (b) Except as set forth on Section 4.9(b) of the Seller Disclosure Schedule, Seller and the Company have established and maintained a system of internal control over financial reporting (as defined in Rule 13a-15 under the Exchange Act) that provides, in all material respects, reasonable assurance regarding the reliability of Seller’s and the Company’s financial reporting and the preparation of Seller’s and the Company’s financial statements for external purposes in accordance with GAAP.
     4.10 Absence of Undisclosed Liabilities. The Company has no Liabilities, except those that (i) are properly reflected on the face of the Company Financial Statements, (ii) have been incurred in the ordinary course of business since the date of the latest balance sheet

27


 

included in the Company Financial Statements, (iii) are set forth on Section 4.10 of the Seller Disclosure Schedule or (iv) are not, individually or in the aggregate, expected to result in Liabilities to the Company and its business greater than $37,500.
     4.11 Real Property.
          (a) Section 4.11(a) of the Seller Disclosure Schedule sets forth a true, complete and correct listing of each parcel of Owned Real Property (including street address, legal description (if known), owner and the Company’s use thereof). With respect to each parcel of Owned Real Property:
          (i) except as set forth on Section 4.11(a)(i) of the Seller Disclosure Schedule, the Company has good, valid, insurable, marketable and fee simple title to such Owned Real Property, free and clear of all Encumbrances (except for Permitted Encumbrances) and Buyer will receive such title and/or interest in the Owned Real Property at the Closing free and clear of all Encumbrances (other than Permitted Encumbrances); and
          (ii) neither Seller nor the Company has leased or otherwise granted to any Person the right to use or occupy such Owned Real Property or any portion thereof.
          (b) Section 4.11(b) of the Seller Disclosure Schedule sets forth a true, complete and correct listing of all Leased Real Property (including street address, legal description (if known), lessor, rent and the Company’s use thereof), and a true, complete and correct list of all lease Contracts for such Leased Real Property. Seller has made available to Buyer true and complete copies of each such lease Contract, as amended through the date hereof. With respect to each such lease Contract:
          (i) the Company has a valid leasehold interest to the leasehold estate in the Leased Real Property granted to the Company pursuant to each such lease Contract;
          (ii) each such lease Contract is, and will continue to be, legal, valid, binding, enforceable and in full force and effect against the parties thereto in accordance with its terms following the consummation of the transactions contemplated hereby;
          (iii) no event has occurred or circumstance exists which, with the delivery of notice, the passage of time or both, would constitute a material breach or default under such lease Contract; and
          (iv) neither Seller nor the Company has assigned, transferred, conveyed, mortgaged, deeded in trust or encumbered any interest in any Leased Real Property held pursuant to such lease Contract.
          (c) Except as set forth on Section 4.11(c) of the Seller Disclosure Schedule, the Company Real Property and all present uses and operations of the Company Real Property comply in all material respects with easements and disposition agreements affecting the Company Real Property and there are no pending or, to the Knowledge of Seller, threatened

28


 

condemnation, fire, health, safety, building, zoning or other land use regulatory proceedings, lawsuits or administrative actions relating to any portion of the Company Real Property or the current use, occupancy or value thereof, nor has the Company or Seller received written notice of any pending or threatened special assessment proceedings affecting any portion of the Company Real Property, in each case except to the extent that such actions or notice would result in a Material Adverse Effect on the Company.
          (d) To the Knowledge of Seller, no fact or condition exists which could result in the termination or material reduction of the current access from the Company Real Property to existing roads or to water, sewer or other utility services presently serving such Company Real Property.
          4.12 Labor and Employment Matters.
          (a) The Company is not a party to a collective bargaining agreement and none of the Company’s employees are represented by a union or other labor organization, association or bargaining agent, and to the Knowledge of Seller, no such organizing efforts are now being conducted or pending with respect to Company employees.
          (b) There are no charges of employment discrimination, sexual harassment or unfair labor practices or strikes, slowdowns, stoppages of work or any other concerted interference with normal operations pending, or to the Knowledge of Seller, threatened against or involving the Company. Since January 1, 2005, the Company is and has been in compliance in all material respects with all applicable Laws respecting labor, employment, fair employment practices, terms and conditions of employment, worker’s compensation, plant closings, immigration, wages and hours, employment discrimination and occupational safety and health requirements.
          (c) During the past two (2) years, the Company has not implemented any layoffs that implicate the Worker Adjustment and Retraining Notification Act of 1988, as amended, or any similar state or local Law.
          (d) Except as set forth on Section 4.12(d) of the Seller Disclosure Schedule, there is no unfair labor practice charge or complaint or any representation petitions or other similar petitions or requests for representation pending, or, to the Knowledge of Seller, proposed or threatened against or involving the Company before the National Labor Relations Board or any other Governmental Authority and there is no litigation, grievance, arbitration proceeding, governmental investigation, citation or Action of any kind pending, or, to the Knowledge of Seller, proposed or threatened against the Company relating to labor, employment, fair employment practices, terms and conditions of employment, worker’s compensation, plant closings, immigration, wages and hours, employment discrimination or occupational safety and health requirements.
          (e) Seller has provided to Buyer a complete and accurate list of all employees employed by the Company as of April 8, 2010, by identification number, and, to the extent such information may be shared consistent with applicable Law, their titles, beginning service dates, current wages (salaries or hourly rates of pay), vacation entitlements and

29


 

guaranteed bonuses. To the extent such information may be shared consistent with applicable Law, Seller has provided to Buyer whether such employees are on inactive status, including lay-off, short-term disability leave, long-term disability leave, pregnancy and parental leave or other extended absence, or are receiving benefits pursuant to workers’ compensation legislation, and specifies the last date of active employment, the reason for the absence and the expected date of return of each such employee. All of the employees of the Company perform functions for and provide services exclusively to the Company.
          4.13 Employee Benefit Plans.
          (a) Set forth on Section 4.13(a) of the Seller Disclosure Schedule are all Benefit Plans. “Benefit Plans” shall mean (i) “employee benefit plans” (within the meaning of Section 3(3) of ERISA, including, without limitation, multiemployer plans within the meaning of Section 3(37) of ERISA), and (ii) all other retirement, deferred compensation, profit sharing, stock purchase, stock option and other equity-based, health and disability insurance, employment, severance, change in control, “golden parachute,” retention, consulting, bonus, incentive, collective bargaining, fringe benefit and all other employee benefit plans, agreements, programs, policies or other arrangements, whether or not subject to ERISA, in each case, (i) that cover or are otherwise applicable to any of the employees or former employees of the Company, (or any dependents or beneficiaries thereof) or (ii) with respect to which the Company has any present or future or actual or contingent Liability (Benefit Plans sponsored or maintained solely by the Company are referred to herein as the “Company Benefit Plans” and Section 4.13(a) of the Seller Disclosure Schedule separately identifies all Company Benefit Plans). Except as set forth on Section 4.13(a) of the Seller Disclosure Schedule, with respect to each Benefit Plan, Seller has provided, or made available, to Buyer a current, accurate and complete copy (or, an accurate description) thereof and any summary plan description, and with respect to each Company Benefit Plan, to the extent applicable: (i) any related trust agreement or other funding instrument, (ii) the most recent determination or opinion letter, and (iii) for the two most recent years, the Form 5500 and attached schedules, audited financial statements and actuarial valuation reports prepared or required to be prepared with respect thereto.
          (b) Except as set forth on Section 4.13(b) of the Seller Disclosure Schedule, (i) each Benefit Plan which is intended to be qualified within the meaning of Section 401(a) of the Code is so qualified and has received a favorable determination letter as to its qualification, and the Company is not aware of any facts or circumstances that could reasonably be expected to cause the loss of such qualification, (ii) no event has occurred that has subjected, and, to the Knowledge of Seller, no condition exists that would subject, the Company, either directly or by reason of its affiliation with any member of its “Controlled Group” (defined as any organization which is a member of a controlled group of organizations within the meaning of Sections 414(b), (c), (m) or (o) of the Code), to any material tax, fine, lien, penalty or other Liability imposed by ERISA, the Code or other applicable Laws, (iii) no nonexempt “prohibited transaction” (as such term is defined in Section 406 of ERISA and Section 4975 of the Code) has occurred with respect to any Benefit Plan, except as would not, individually or in the aggregate, reasonably be expected to result in material Liability of the Company, (iv) none of the Company or any member of the Controlled Group has at any time within the past six (6) years maintained, sponsored or contributed to, or has or had any Liability or obligation in respect of, any employee benefit plan that is subject to Title IV of ERISA, including any

30


 

“multiemployer plan” (as defined in Section 4001(a)(3) of ERISA), (v) the Company has not incurred any current or projected Liability in respect of post-employment or post-retirement health, medical or life insurance benefits for Company employees or former employees, except as required under COBRA, (vi) each Benefit Plan has been established and operated in compliance in all material respects with all applicable Laws and (vii) there are no pending or, to the Knowledge of Seller, threatened Claims, disputes or investigations involving or related to any Benefit Plan that would reasonably be expected to result in a material Liability.
          (c) Except as set forth on Section 4.13(c) of the Seller Disclosure Schedule, neither the execution of this Agreement nor the transactions contemplated hereby (whether alone or in connection with any other event(s)) could (i) result in severance pay or any increase in severance pay upon any termination of employment of any Company employee, (ii) accelerate the time of payment or vesting or result in any payment or funding (through a grantor trust or otherwise) of compensation or benefits under, or increase the amount payable or result in any other material obligation pursuant to, any of the Benefit Plans with respect to which the Company or Buyer would be responsible, (iii) limit or restrict the right of the Company to merge, amend or terminate any of the Benefit Plans, or (iv) result in payments under any of the Benefit Plans which would not be deductible under Section 280G of the Code.
          (d) All amounts which are required to be paid or contributed by the Company in respect of any Benefit Plan (A) for any period ending prior to December 31, 2008, shall have been fully and timely paid or contributed; and (B) for any period thereafter, shall have been either fully and timely paid or contributed or properly accrued as a reserve.
     4.14 Litigation. Except as set forth on Section 4.14 of the Seller Disclosure Schedule, there is no, and, during the three (3) years prior to the date hereof, has not been any, material Action pending or, to the Knowledge of Seller, threatened, against or involving (a) the Company or (b) to the Knowledge of Seller, any current or former officer, director or employee of the Company which would reasonably be expected to result in a Liability to the Company. Except as set forth on Section 4.14 of the Seller Disclosure Schedule, the Company is not subject to any material Governmental Order and no notice of any Action, governmental investigation or inquiry involving the Company, whether pending or, to the Knowledge of Seller, threatened, has been received by the Company or Seller during the last three (3) years.
     4.15 Environmental, Health and Safety Matters.
          (a) The Company is and, during the five (5) years prior to the date hereof, has been, in compliance in all material respects with all applicable Environmental Laws, which compliance has included obtaining and complying at all times and in all material respects with all material permits required under applicable Environmental Laws.
          (b) Except as set forth on Section 4.15(b) of the Seller Disclosure Schedule, the Company has not, during the five (5) years prior to the date hereof, received any written notice, Claim or report from any Governmental Authority or third party regarding either (i) any material violation of Environmental Laws by the Company; (ii) any allegation of any actual or potential material responsibility or Liability of the Company under Environmental Laws; or (iii) relating to any disposal, release or threatened release of, or exposure to, any Hazardous

31


 

Materials or Petroleum for which the Company has potential Liability except, in the case of either (i), (ii) or (iii) above, with regard to matters that have been fully and finally resolved prior to the date hereof without future obligation.
          (c) The Company has not used, stored, treated, transported, manufactured, refined, handled, produced, emitted, released, disposed of, arranged for or permitted the disposal of, or exposed any Person to, any Hazardous Materials or Petroleum, including on, under, at or from the Company Real Property, except in compliance in all material respects with applicable Environmental Law and as would not give rise to any material Liability or material investigatory, corrective or remedial obligation pursuant to any Environmental Law.
          (d) The Company does not own or operate any property or facility and has not previously owned or operated any property or facility which is or has been contaminated by any Hazardous Material or Petroleum so as to give rise to any material Liabilities of the Company or material investigatory, corrective or remedial obligations of the Company under Environmental Laws. There is no asbestos contained in or forming part of any building, structure or asset at the Company Real Property except for such material that is being maintained in compliance with applicable Environmental Laws and would not give rise to any material Liabilities. Except as set forth on Section 4.15(d) of the Seller Disclosure Schedule, there is not now nor has there ever been any asbestos or mercury contained in or forming part of any products currently or previously manufactured, distributed or sold by the Company or any of its predecessors (or any other Person for whose conduct any of them are or may be responsible).
          (e) The Company is not subject to any Action or any Governmental Order pursuant to Environmental Law or relating to any Hazardous Material or Petroleum.
          (f) The Company has not, expressly or by operation of Law, assumed, undertaken, or provided an indemnity with respect to any material Liability or any material investigatory, corrective or remedial obligation, of any other Person relating to Environmental Laws, including any Release of Hazardous Materials or Petroleum.
          (g) Seller has made available to Buyer true, complete and correct copies of all material environmental site assessments, audits, reports and all other documents materially bearing on environmental, health or safety Liability related to the past or current operations, properties or facilities of the Company (including, without limitation, the environmental condition of the Company Real Property), in each case which are in the possession of Seller or the Company or under the reasonable control of Seller or the Company.
          (h) Notwithstanding anything to the contrary contained in this Agreement, the representations and warranties in this Section 4.15 are the sole and exclusive representations and warranties of Seller concerning environmental matters, including any matters arising under Environmental Laws.
     4.16 Compliance with Law.
          (a) Except as set forth on Section 4.16(a) of the Seller Disclosure Schedule, (i) the Company is, and since January 1, 2005, has been, in possession and operating in

32


 

compliance in all material respects with all franchises, grants, authorizations, licenses, permits, easements, variances, exceptions, Consents, certificates, approvals and orders of any Governmental Authority material to its business as it is now being conducted (the “Company Permits”), (ii) the Company Permits are valid and subsisting and, as of the date of this Agreement, no modification, termination, suspension or cancellation of any of the Company Permits is pending or, to the Knowledge of Seller, threatened, (iii) the Company is and has conducted its business in compliance in all material respects with the requirements, standards, criteria and conditions set forth in the Company Permits and (iv) the Company or Seller has delivered to Buyer true, complete and correct copies of all material Company Permits.
          (b) Except as set forth on Section 4.16(b) of the Seller Disclosure Schedule, (i) the Company is conducting and has conducted its business and operations since January 1, 2005 in compliance in all material respects with all applicable Laws, (ii) the Company is conducting and has conducted its business and operations in compliance in all material respects with (A) the reporting requirements of Section 519 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 321 et seq. (including the applicable rules and regulations thereunder and the regulations promulgated pursuant thereto, the “FD&C Act”), including compliance with the written procedures, record-keeping and the U.S. Food and Drug Administration (“FDA”) reporting requirements for Medical Device Reporting set forth in 21 C.F.R. Part 803, (B) the Quality System Regulation set forth in 21 C.F.R. Part 820, (C) the rules and regulations of the FDA and comparable foreign, state and local rules and regulations regarding clinical investigations, good clinical practices, and good laboratory practices, and (D) all other rules and regulations of the FDA and comparable foreign, state and local rules and regulations and (iii) the Company has not received any written notice or communication from any Governmental Authority alleging noncompliance with any applicable Law.
          (c) Except as set forth on Section 4.16(c) of the Seller Disclosure Schedule, the Company (i) has not received any Form 483s, shutdown or import or export prohibition, warning letter or untitled letters from the FDA or similar correspondence or notices or Actions from any other Governmental Authority asserting noncompliance with any applicable Law, Company Permit or other requests or requirements of a Governmental Authority during the last five (5) years and (ii) has not received any written communication from any Governmental Authority or been notified in writing during the last five (5) years that any Company Permit is withdrawn or modified or that such an action is under consideration except, in each case, as would not be material to the Company, and the Company has not received any requests or requirements to make changes to any product or proposed product that, if not complied with, would be material to the Company.
          (d) The clinical trials conducted by or on behalf of or sponsored by the Company or in which the Company test its products were and, if still pending, are being conducted in all material respects (i) to the Knowledge of Seller in accordance with the relevant clinical trial protocol and generally accepted good clinical medical and scientific research practices and procedures and (ii) in accordance with applicable Law, and all applicable rules and regulations of the FDA and comparable foreign, state and local rules and regulations. No investigational device exemption filed by or on behalf of the Company with the FDA has been terminated, held or suspended by the FDA.

33


 

          (e) Seller has provided to Buyer true, to the extent within the possession or in the control of Seller or the Company, complete and correct copies of the following regarding or involving the Company or any third party manufacturer or supplier of the Company: (A) all material warning letters, untitled letters, notices of adverse findings and similar correspondence; (B) all material submissions, reports or other documents (including any telephone or meeting notes) related to recalls or corrections and removals reports, including all correspondence to and from the FDA and the Company related thereto; and (C) all material reports and other written communication (including any telephone or meeting notes) that pertain to assessing compliance of the Company’s or the Company’s suppliers’ operations with respect to the Company’s products or any third party manufacturer’s production of the Company’s products with respect to the FD&C Act or other applicable Laws and regulations, including all inspection reports and lists of observations relating to inspections for compliance with the FD&C Act.
     4.17 Tax Matters.
          (a) Except as set forth on Section 4.17(a) of the Seller Disclosure Schedule, (i) Seller and the Company have timely filed with the appropriate Governmental Authority all material Tax Returns required to have been filed by or with respect to the Company, and each such Tax Return is correct and complete in all material respects, (ii) all Taxes of the Company (and Seller, with respect to the Company), whether or not shown as due and payable on a Tax Return, have been timely paid and (iii) neither the Company nor any consolidated, combined, affiliated or similar group of which the Company is a member is currently the beneficiary of any extension of time within which to file any material Tax Return.
          (b) Except as set forth on Section 4.17(b) of the Seller Disclosure Schedule, (i) neither the Company nor any consolidated, combined, affiliated or similar group of which the Company is a member has waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency, (ii) no deficiencies for Taxes with respect to the Company or any consolidated, combined, affiliated or similar group of which the Company is a member have been claimed, proposed or assessed which deficiency remains unresolved and (iii) no audit or other proceeding relating to Taxes of the Company or any consolidated, combined, affiliated or similar group of which the Company is a member is pending or has been threatened in writing.
          (c) Except as set forth on Section 4.17(c) of the Seller Disclosure Schedule, there are no Encumbrances for Taxes on or against any material Assets of the Company, other than Encumbrances for current Taxes not due and payable or being contested in good faith.
          (d) Since January 2, 2010, the Company has not incurred any Liability for Taxes outside the ordinary course of business.
          (e) Since February 14, 2001, the Company has not been a member of any affiliated group filing a consolidated Tax Return for U.S. federal income tax purposes other than the affiliated group the common parent of which is Seller.
          (f) The Company is not a party to any Tax sharing agreement or Tax allocation agreement.

34


 

          (g) The Company has not been a party to any transaction intended to qualify under Section 355 of the Code at any time in the last two years.
          (h) Except as set forth on Section 4.17(h) of the Seller Disclosure Schedule, the Company has withheld and paid all material Taxes required to have been withheld and paid in connection with amounts paid to any employee, independent contractor, creditor or stockholder of the Company.
          (i) Neither the Company nor any consolidated, combined, affiliated or similar group of which the Company is a member has been a party to a transaction that is a “listed transaction,” as such term is defined in Treasury Regulations Section 1.6011-4.
     4.18 Contracts.
          (a) “Material Contracts” shall include any of the following Contracts to which the Company is a party, each of which is listed on Section 4.18(a) of the Seller Disclosure Schedule:
          (i) any Contract with any customer of the Company representing revenues of at least $1,000,000 for the Company for 2008 and/or 2009;
          (ii) any Contract with any Significant Supplier (other than any purchase orders entered into in the ordinary course of business that are subject to customary and standard terms and conditions);
          (iii) any Contract with any officer, director or employee, or any Affiliate thereof or any Affiliate of the Company, on the one hand, and the Company, on the other hand (other than (A) offer letters for employment on an at-will basis and (B) customary confidentiality, assignment of inventions and/or noncompetition or other similar arrangements);
          (iv) any outstanding loan agreements, guarantee agreements, letters of credit, mortgages, promissory notes or other documents relating to Indebtedness of the Company (other than intercompany loans and Indebtedness between the Company and Seller or any Subsidiary of Seller that will be repaid or terminated at or prior to the Closing pursuant to Section 6.9);
          (v) any Contract to which the Company is a party which prohibits the Company from entering into any line of business or supplying products to any customer or potential customer in any part of the world (other than any Contract with a customer or supplier entered into in the ordinary course of business);
          (vi) any Contract to buy or sell a material portion of the Assets or business of the Company;
          (vii) any material inbound or outbound license for Intellectual Property owned or licensed by the Company;

35


 

          (viii) any Contract to which the Company is a party or by which the Company or any of the Assets are bound for any material cleanup, abatement, investigation or other action in connection with any release or threatened release of a Hazardous Material, the payment of any existing material environmental Liabilities, or correction of any material violation of Environmental Laws;
          (ix) any Contract in which the Company has granted “most favored nation” pricing provisions or exclusive marketing or distribution rights relating to any products or territory or has agreed to purchase a minimum quantity of goods or services or has agreed to purchase goods or services exclusively from a specified Person (or group of Persons);
          (x) any Contract concerning the establishment or operation of a partnership, joint venture or similar enterprise relating to the Company, or to which the Company is a party;
          (xi) any Contract to which the Company is a party or by which the Company is bound with any Governmental Authority;
          (xii) any lease Contract relating to the Leased Real Property;
          (xiii) each operating lease (as lessor or lessee) of tangible personal property involving payments in excess of $250,000; and
          (xiv) any Organizational Document of the Company.
          (b) Except as set forth on Section 4.18(b) of the Seller Disclosure Schedule, (i) there have been made available to Buyer true and complete copies of all of the Material Contracts (including all amendments, modifications, extensions, renewals, guaranties and other related agreements with respect thereto), (ii) all of the Material Contracts are legal, valid and binding upon and enforceable against the Company and, to the Knowledge of Seller, the other parties thereto, in accordance with their terms, (iii) the Company is not in default or breach in any material respect under any Material Contract nor does any condition exist that with notice or lapse of time or both would constitute such a default or breach thereunder by the Company, and, to the Knowledge of Seller, no other party to any Material Contract is in default or breach in any material respect any Material Contract, nor does any condition exist that with notice or lapse of time or both would constitute such a default or breach thereunder by any such party and (iv) the Company has not received written notice that any party to any Material Contract intends to cancel or terminate any such Material Contract or to not exercise any option to renew thereunder and, to the Knowledge of Seller, no party to any Material Contract intends to exercise any right of cancellation, termination, acceleration or modification under any such Material Contract.
     4.19 Intellectual Property.
          (a) Section 4.19(a) of the Seller Disclosure Schedule lists all registrations and applications for registration of Intellectual Property that has been filed with or issued or registered by a Governmental Authority and that is owned by the Company, including, as

36


 

applicable, the owner, the jurisdiction, the serial/application number, the patent or registration number, the filing date, the issuance or registration date, the registrant and the registrar thereof. With respect to each item required to be listed on Section 4.19(a) of the Seller Disclosure Schedule, the Company is the sole owner or otherwise possesses all right, title and interest in and to the item, free and clear of all Encumbrances (other than Permitted Encumbrances).
          (b) The Company owns or otherwise has a right to use pursuant to Contracts that are valid and enforceable against the Company and, to the Knowledge of Seller, the other parties thereto, in accordance with their terms, all Intellectual Property necessary for or otherwise material to the conduct of the Company’s business (collectively, the “Company Intellectual Property”); provided, however, the foregoing representation and warranty shall not be deemed to be a representation or warranty with respect to infringement, misappropriation, dilution or other violation of any Intellectual Property rights of any other Person (which is covered in Section 4.19(c) below). The consummation of the transactions contemplated by this Agreement shall not result in the loss or impairment of any material rights of the Company in any Company Intellectual Property.
          (c) (i) The Company has not, since January 1, 2007, infringed, misappropriated, diluted or otherwise violated any material Intellectual Property rights of any other Person, and (ii) except as set forth on Section 4.19(c)(ii) of the Seller Disclosure Schedule, to the Knowledge of Seller, no Person has, since January 1, 2007, infringed, misappropriated, diluted or otherwise violated any material Intellectual Property rights of the Company.
          (d) Except as set forth on Section 4.19(d) of the Seller Disclosure Schedule, with respect to each item of Intellectual Property required to be listed on Section 4.19(a) of the Seller Disclosure Schedule: (i) the item is not subject to any outstanding injunction, judgment, order, decree, ruling or charge; (ii) no Action is pending or, to the Knowledge of Seller, threatened which challenges the validity, enforceability, use or ownership of the item; and (iii) the item is subsisting, has not been adjudicated as invalid or unenforceable and, to Seller’s Knowledge, there are no facts or circumstances reasonably likely to give rise to such an adjudication. The Company has used all commercially reasonable efforts to maintain, protect and enforce the material Company Intellectual Property.
          (e) Except for those trademarks set forth on Section 4.19(e) of the Seller Disclosure Schedule, all of the trademarks and service marks owned or used by the Company and material to the operation of its business are registered or subject to a pending application for registration with the United States Patent and Trademark Office or the appropriate foreign agency.
          (f) All past and present employees and independent contractors of, and consultants to, the Company have entered into agreements pursuant to which such employee, independent contractor or consultant agrees to protect the confidential information of the Company and, with respect to those employees, independent contractors or consultants who contributed to the development of any Intellectual Property for the Company, assign to the Company all Intellectual Property authored, developed or otherwise created by such employee, independent contractor or consultant in the course of his, her, or its employment or other relationship with the Company, without further consideration or any restrictions or obligations

37


 

on the use or ownership of such Intellectual Property, and such agreements are valid and enforceable against the Company and, to the Knowledge of Seller, the other parties thereto, in accordance with their terms.
          (g) In the last twelve (12) months, there have been no failures, breakdowns, continued substandard performance or other adverse events affecting any software, firmware, hardware, networks, interfaces and platforms owned or used by the Company (the “Company Systems”) that have caused or could reasonably be expected to result in a material disruption or interruption in or to the use of the Company Systems and/or the conduct of the business of the Company.
          (h) Except as set forth on Section 4.19(h) of the Seller Disclosure Schedule, (i) the Company operates its business independently from Seller and its Affiliates (other than the Company), and does not use and is not dependent on any facilities, resources, properties or Assets of Seller or its Affiliates (other than the Company) and (ii) all Company Systems (other than software) are owned by or under the control of the Company.
     4.20 No Brokers. Except for Bank of America Merrill Lynch, the fees of which are the sole responsibility of Seller, Seller has not engaged or made any agreement with any broker, finder or similar agent or any Person or firm which will result in the obligation of Buyer or the Company to pay any finder’s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby. The engagement letter, dated as of November 6, 2009, between Thoratec Corporation and Merrill, Lynch, Pierce Fenner & Smith Incorporated does not include any obligation on the part of the Company to engage Bank of America Merrill Lynch or any of its Affiliates for any future services or any transaction (other than the transactions contemplated by this Agreement).
     4.21 Absence of Changes. Except as set forth on Section 4.21 of the Seller Disclosure Schedule, since January 2, 2010, (a) the business of the Company has been operated in the ordinary course of business and (b) the Company has not taken any action which, if taken after the date hereof, would be a breach of Section 6.3(a).
     4.22 Unlawful Payments. Neither the Company, nor any Representative of the Company, has directly or indirectly made any contribution, gift, bribe, rebate, payoff, influence payment, kickback or other payment to any Person in respect of the Company’s business, private or public, regardless of what form, in violation in any material respect of any applicable Law.
     4.23 Affiliate Transactions. Except as set forth on Section 4.23 of the Seller Disclosure Schedule and except for Contracts for the payment of wages, salaries, bonuses or other compensation to officers or directors of the Company for services performed in the ordinary course of business (all of which are set forth on Section 4.23 of the Seller Disclosure Schedule), the Company is not, and has not been during the last three (3) years, party to any Contract, transaction or course of dealing with Seller, any of Seller’s Subsidiaries, any other Person in which Seller holds, directly or indirectly, controlling Equity Interests or any of their respective directors or officers.

38


 

     4.24 Significant Customers and Suppliers.
          (a) (i) Section 4.24(a)(i) of the Seller Disclosure Schedule sets forth a true, complete and correct customer list showing the ten (10) largest customers by revenues from the Company during the twelve (12) month period ended on the date of the latest balance sheet included in the Company Financial Statements (the customers described in the foregoing clause (i) being referred to herein, individually, as a “Significant Customer” and, collectively, as the “Significant Customers”), and (ii) Section 4.24(a)(ii) of the Seller Disclosure Schedule sets forth a true, complete and correct supplier list showing (A) the ten (10) largest suppliers by sales to the Company during the twelve (12) month period ended on the date of the latest balance sheet included in the Company Financial Statements and (B) all suppliers of the Company (other than suppliers covered by clause (A) above) who supply products that represented $100,000 in sales during the twelve (12) month period ended on the date of the latest balance sheet included in the Company Financial Statements and who are, to the Knowledge of Seller, potentially the sole source to the Company of such supply (other than public utilities) (the suppliers described in clause (ii) being referred to herein, individually, as a “Significant Supplier” and, collectively, as the “Significant Suppliers”).
          (b) Except as set forth on Section 4.24(b) of the Seller Disclosure Schedule, since January 1, 2009, no Significant Customer or Significant Supplier has (i) stopped, or indicated in writing an intention to stop, purchasing from or supplying the Company, (ii) materially reduced, or indicated in writing an intention to materially reduce, its purchase of or provision of goods or services to the Company, or (iii) changed, or indicated in writing an intention to change, materially, the terms and conditions on which it is prepared to purchase from or supply the Company. During the last three (3) months, no Significant Customer has indicated to the Company or Seller in writing of its intention to return products sold by the Company with a value in excess of $100,000.
     4.25 Insurance. Section 4.25 of the Seller Disclosure Schedule sets forth an accurate list of all insurance policies carried by, or covering, the Company (the “Insurance Policies”). The Company has delivered to Buyer true, complete and correct copies of all such Insurance Policies. With respect to each such Insurance Policy: (a) such policy is legal, valid, binding and enforceable in accordance with its terms and, except for policies that have expired under their terms in the ordinary course of business, is in full force and effect, (b) except as set forth on Section 4.25(b) of the Seller Disclosure Schedule, the Company is not in breach or default (including any breach or default with respect to the payment of premiums or the giving of notice) in any material respect, and no event has occurred which, after notice or the lapse of time or both, would constitute a breach or default or permit termination or modification, under such policy and (c) such policy is occurrence based. All premiums due and payable under all such policies have been paid. To the Knowledge of Seller, there have been no threatened terminations of, or material premium increases with respect to, any such policies.
     4.26 Warranties; Products. Except as set forth on Section 4.26 of the Seller Disclosure Schedule, (i) no Claims have been made or are, to the Knowledge of Seller, threatened under the Product Warranties, (ii) to the Knowledge of Seller, there exists no event or circumstance, which after notice or the passage of time or both, might create or result in Liabilities under any of the Product Warranties in excess of the Liabilities incurred under such Product Warranties on average during the past two (2) years, (iii) there have been no statements, citations or decisions by any Governmental Authority or any product testing laboratory stating that any Customer

39


 

Offering is unsafe or fails to meet any standards promulgated by such Governmental Authority or testing laboratory in any material respect, and (iv) there have not been any mandatory or voluntary product recalls with respect to any Customer Offering and, to the Knowledge of Seller, there is no fact relating to any Customer Offering that may impose a duty on the Company to recall any Customer Offering.
     4.27 Sufficiency of Assets. The Assets constitute all of the tangible Assets, rights and properties (other than Owned Real Property and the Leased Real Property) necessary and sufficient for the conduct of the Company’s business substantially in the same manner as presently conducted.
     4.28 No Implied Representations. Seller acknowledges that Buyer is making no representation or warranty whatsoever, express or implied, beyond those expressly given in Article V. Notwithstanding the foregoing, any Claims involving fraud, intentional misrepresentation or willful misconduct on the part of Buyer or any of its Affiliates shall not be precluded, impacted or otherwise affected by this Section 4.28.
ARTICLE V.
REPRESENTATIONS AND WARRANTIES OF BUYER
          Buyer hereby represents and warrants to Seller as follows:
     5.1 Organization. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, with the requisite corporate power and authority to conduct its business as it is presently being conducted. Buyer is duly qualified or licensed to do business in each jurisdiction in which the property owned, leased or operated by Buyer or the nature of the business conducted by Buyer makes such qualification necessary, except in any such jurisdictions where the failure to be duly so qualified or licensed would not have a Material Adverse Effect.
     5.2 Authorization. Buyer has all requisite corporate power and authority and has taken all corporate action necessary, to execute and deliver this Agreement and the other agreements contemplated hereby, to consummate the transactions contemplated hereby and to perform its obligations hereunder. This Agreement and the other agreements contemplated hereby have been duly executed and delivered by Buyer and, assuming the due authorization, execution and delivery of this Agreement and such other agreements by Seller, are legal, valid and binding obligations of Buyer, enforceable against Buyer in accordance with their respective terms, except as may be limited by the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other similar Laws relating to or affecting creditors’ rights generally and general equitable principles (whether considered in a proceeding in equity or at law).
     5.3 Non-Contravention. Neither the execution and delivery of this Agreement or the other agreements contemplated hereby by, nor the consummation of the transactions contemplated hereby or thereby, will (a) conflict with or result in a breach or violation of any provision of the Organizational Documents of Buyer or, to the Knowledge of Buyer, any resolution of the board of directors of Buyer, (b) violate or result in a default or breach of (or an

40


 

event that with notice or lapse of time or both would become a default or breach) or give rise to any right of termination, modification, Consent or acceleration under, or result in the loss of any material right or the imposition of any Liability under, any material Contract of Buyer, (c) subject to the Consents of Governmental Authorities described in Section 4.4, violate any Law to which Buyer is subject.
     5.4 Government Authorizations. Except for any filings and Consents required under the HSR Act, no Consent of, with or to any Governmental Authority is required to be obtained or made by Buyer or its Subsidiaries in connection with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby.
     5.5 Litigation. Except as set forth on Section 5.5 of the Buyer Disclosure Schedule, there is no material Action pending or, to the Knowledge of Buyer, threatened against Buyer that would have a Material Adverse Effect on Buyer.
     5.6 No Brokers. Buyer has not engaged or made any agreement with any broker, finder or similar agent or any Person or firm which will result in the obligation of Seller or any of its Affiliates to pay any finder’s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.
     5.7 Financing. Buyer has, and will have at Closing, access to sufficient funds to consummate the transactions contemplated by this Agreement and to satisfy all other costs and expenses arising in connection herewith.
     5.8 No Implied Representation. Buyer acknowledges that Seller is making no representation or warranty whatsoever, express or implied, beyond those expressly given in Article IV of this Agreement, including any implied warranty of merchantability or suitability as to the properties or Assets of the Company. In addition, without limiting the generality of the foregoing, Buyer acknowledges that any cost estimates, projections and predictions contained or referred to in the materials that have been provided to Buyer are not and shall not be deemed to be representations or warranties of Seller unless such matters are representations or warranties covered in Article IV. Notwithstanding the foregoing, any Claims involving fraud, intentional misrepresentation or willful misconduct on the part of Seller, the Company or any of their respective Affiliates shall not be precluded, impacted or otherwise affected by this Section 5.8.
ARTICLE VI.
COVENANTS OF SELLER AND BUYER
          Seller and Buyer each covenant with the other as follows:
     6.1 Further Assurances and Regulatory Approvals.
          (a) Subject to the terms and conditions of this Agreement, each Party shall use its reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things necessary, proper or advisable under applicable Law to consummate and make effective the transactions contemplated by this Agreement. Without limiting the generality of the foregoing, the Parties will use their respective reasonable best efforts to (i) prepare and file as soon as reasonably

41


 

practicable all forms, registrations and notices relating to antitrust, competition, trade or other regulatory matters that are required by applicable Law to be filed in order to consummate the transactions contemplated hereby, and take such commercially reasonable actions as are reasonably necessary to obtain any Consents from, or to avoid any Action by, any Governmental Authority relating to antitrust, competition, trade or other regulatory matters (collectively, “Regulatory Approvals”), including any Notification and Report Forms and related material required in connection with the HSR Act with the United States Federal Trade Commission (“FTC”) and with the Antitrust Division of the United States Department of Justice (“Antitrust Division”) in connection with the HSR Act (which shall be filed no later than ten (10) Business Days following the date of this Agreement), (ii) take all actions reasonably necessary to cause all conditions set forth in Articles VII and VIII to be satisfied as soon as practicable (provided that nothing in this Section 6.1 shall require Seller to waive any of the conditions set forth in Article VII or require Buyer to waive any of the conditions set forth in Article VIII) and (iii) execute and deliver any additional instruments necessary to fully carry out the purposes of this Agreement.
          (b) Each Party shall furnish all information required to be included in any application or other filing to be made pursuant to the rules and regulations of any Governmental Authority in connection with the transactions contemplated hereby. Subject to applicable Law and the attorney-client and similar applicable privileges, Seller and Buyer shall have the right to review in advance, and, to the extent reasonably practicable, each will consult the other on, all the information relating to the other and each of their respective Subsidiaries and Affiliates that appears in any filing made with, or written materials submitted to, any Governmental Authority in connection with the transactions contemplated hereby; provided, however, that each Party may, at its discretion, impose reasonable safeguards to prevent the disclosure of competitively-sensitive information of such Party to the other Party.
          (c) Each Party shall (i) subject to Section 6.1(d) below, respond as promptly as reasonably practicable to any inquiries or requests for additional information and documentary material received from the FTC or the Antitrust Division and to all inquiries and requests received from any State Attorney General or other Governmental Authority in connection with Regulatory Approvals and antitrust matters, (ii) not extend any waiting period or agree to refile under the HSR Act (except with the prior written consent of the other Parties hereto, which consent shall not be unreasonably withheld, conditioned or delayed) and (iii) not enter into any agreement with the FTC or the Antitrust Division agreeing not to consummate the transactions contemplated by this Agreement.
          (d) In connection with and without limiting the foregoing, Buyer and Seller shall cooperate in good faith to resolve any objections that may be raised by any Governmental Authority. Each Party shall, subject to applicable Law and except as prohibited by any applicable representative of any applicable Governmental Authority: (i) promptly notify the other Parties of any material written communication to that Party from the FTC, the Antitrust Division, any State Attorney General or any other regulatory Governmental

42


 

Authority concerning this Agreement or the transactions contemplated hereby, and permit the other Parties to review in advance (and to consider any comments made by the other Parties in relation to) any proposed written communication to any of the foregoing, (ii) not participate in or agree to participate in any substantive meeting, telephone call or discussion with any Governmental Authority in respect of any filings, investigation or inquiry concerning this Agreement or the transactions contemplated hereby unless it consults with the other Parties in advance and, to the extent permitted by such Governmental Authority, gives the other Parties the opportunity to attend and participate in such meeting, telephone call or discussion and (iii) subject to the attorney-client and similar applicable privileges, furnish outside legal counsel for the other Parties with copies of all correspondence, filings, and written communications (and memoranda setting forth the substance thereof) between such Party and its Affiliates and their respective Representatives on the one hand, and any Governmental Authority or its members or their respective staffs on the other hand, with respect to this Agreement and the transactions contemplated hereby.
     6.2 Access by Buyer. From the date hereof through the Closing, Seller shall permit (and shall cause its Representatives to permit) Buyer and its Representatives to have access (including the right to make copies of documents) at reasonable times within normal business hours, to all personnel, books, records (including Tax records), Contracts, properties, Assets, offices, customers and suppliers of the Company as may be reasonably requested by Buyer, and to discuss the business of the Company with such members of management, officers, counsel and accountants of or for the Company as Buyer and its Representatives may reasonably request. Any information furnished to Buyer or which Buyer receives in exercising its rights pursuant to this Section 6.2 shall be subject to the terms of Section 6.5 hereof; provided, however, that (a) any such investigation shall be conducted in such a manner as not to interfere unreasonably with the conduct of Seller’s business, (b) Seller shall not be required to take any action which would constitute a waiver of the attorney-client privilege if Seller determines in good faith that any requested disclosure would cause any such waiver, and (c) Seller need not supply Buyer with any access or information which Seller is under a legal obligation not to supply if Seller determines in good faith that any requested disclosure would cause a breach of such legal obligation; provided, that in the case of the foregoing clauses (b) and (c), Seller shall provide Buyer with details regarding the type and nature of the information that is prohibited from being disclosed (to the extent that Seller is able to provide such details without compromising such attorney-client privilege or violating such legal obligation). Without Seller’s prior written permission, Buyer and its Representatives shall not be entitled to conduct any intrusive environmental investigation, including any collection of samples of surface or subsurface soil, surface water, groundwater, wastewaters, building materials or any other environmental media. The investigation contemplated by this Section 6.2 shall not affect or otherwise diminish or obviate in any respect, or affect Buyer’s right to rely upon, any of the representations, warranties or covenants contained in this Agreement or the indemnification rights of the Buyer Indemnified Parties contained in this Agreement.
     6.3 Conduct of Business.
          (a) From the date hereof through the Closing, Seller shall (and shall cause the Company to), except as expressly required by this Agreement, and except as expressly set forth on Section 6.3 of the Seller Disclosure Schedule, or as consented to by Buyer in writing, (a) operate the business of the Company in the ordinary course of business, (b) use its reasonable best efforts to preserve and maintain its relationships with the customers, suppliers and employees of the Company and (c) use its reasonable best efforts to preserve the goodwill and ongoing operations of the Company. Without limiting the generality of the foregoing, the

43


 

Company shall not, except as expressly required by this Agreement, except as expressly set forth on Section 6.3 of the Seller Disclosure Schedule or as consented to by Buyer in writing (which consent Buyer shall not, acting from Buyer’s own point of view, unreasonably withhold), take any of the following actions from the date hereof through the Closing:
          (i) enter into or terminate any Material Contract, or extend, materially modify or renew any Material Contract (except for extensions and renewals at the end of the applicable term of the Contract in the ordinary course of business);
          (ii) sell, assign, transfer, convey, lease, mortgage, pledge or otherwise dispose of or encumber any material Assets of the Company, except for Permitted Encumbrances and Encumbrances that will be released prior to the Closing;
          (iii) increase the compensation or benefits of any Company employee (except for increases in salary or hourly wage rates, in the ordinary course of business) or enter into any employment agreement (other than the assignment from Seller of any employment agreement as specifically contemplated by Section 6.4(f)(ii)), severance agreement, or similar agreement or arrangement with any Company employee at the “Vice President” level or higher or with any other Company employee whose annual base salary exceeds $150,000 or any change in control agreement with any Company employee;
          (iv) (A) assume, guarantee, endorse or otherwise become liable or responsible (whether directly, contingently or otherwise) for any material Liabilities of any Person (other than in connection with entering into (I) Contracts that will be terminated in accordance with Section 6.9 or (II) Material Contracts in accordance with this Section 6.3), (B) enter, make any loans, advances or capital contributions to or investments in any Person (other than, with respect to loans and advances, to employees in the ordinary course of business in connection with travel or entertainment expenses) or (C) incur any Indebtedness;
          (v) settle or compromise, or agree to settle or compromise, any Action (whether or not commenced prior to the date of this Agreement), other than settlements or compromises of Actions involving solely money damages not in excess of $100,000; provided, however that the aggregate amount paid in connection with the settlement or compromise of all such disputes and Claims shall not exceed $300,000;
          (vi) amend or modify any provision of its Organizational Documents;
          (vii) issue any Equity Interests; declare, set aside or make any payment or distribution of Cash or other property with respect to its Equity Interests (other than any distribution or similar action in accordance with the second sentence of Section 6.9); or purchase, redeem or otherwise acquire any of its Equity Interests;
          (viii) acquire (by merger, exchange, consolidation, acquisition of equity or Assets or otherwise) any corporation, partnership, joint venture or other business organization or division or the material Assets thereof (other than inventory or supplies in the ordinary course of business), or adopt a plan of complete or partial liquidation,

44


 

dissolution, merger, consolidation, restructuring, recapitalization or other reorganization of the Company;
          (ix) fail to file (or cause to be filed), on or prior to the due date thereof, all Tax Returns required to be filed prior to the Closing Date for all Tax periods ending on or before the Closing Date;
          (x) make or change any material Tax election other than in the ordinary course of business, adopt any accounting or Tax accounting method, change any accounting or Tax accounting method, enter into any closing agreement, settle any material Tax Claim or assessment or consent to any material Tax Claim or assessment;
          (xi) directly or indirectly engage in any material transaction with Seller, any of Seller’s Subsidiaries, any other Person in which Seller holds, directly or indirectly, controlling Equity Interests or any of their respective directors or officers, except for those transactions that will be terminated in accordance with Section 6.9;
          (xii) except as set forth in the Company’s capital expenditures budget (a copy of which has been made available to Buyer) make capital expenditures (or any commitment therefor) in excess of $100,000 in the aggregate, or fail to make any budgeted capital expenditures in excess of $25,000 in the aggregate;
          (xiii) make any change with respect to the payment of accounts payable or accrued expenses or the collection of the accounts receivable, including any acceleration or deferral of the payment or collection thereof, as applicable;
          (xiv) make any material change in the manner in which the Company extends discounts or credits to customers;
          (xv) begin to occupy and use any material facility or office or occupy or use any Company Real Property in a manner materially different than such Company Real Property is occupied or used as of the date hereof;
          (xvi) other than the taking of any action required by this Agreement, engage in any employee layoff activities that would trigger the Worker Adjustment and Retraining Notification Act of 1988, as amended, or any similar state or local plant closing or mass layoff statute, rule or regulation;
          (xvii) hire or terminate any management level employee having the title of Vice President (or performing services ordinarily performed by a person having such title) or any management level employee having a higher title (provided that the Company shall be permitted to terminate any such persons for “cause”);
          (xviii) change any accounting methods, principles or policies used by the Company or by Seller with respect to the Company, unless required by GAAP or applicable Law;

45


 

          (xix) transfer, sell, assign or license to any Person, or otherwise dispose of, or incur any Encumbrance on, any rights to the Company Intellectual Property material to the business of the Company, other than in the ordinary course of business or take any action or knowingly fail to take any action that would be reasonably likely result in the loss, lapse, abandonment, invalidity or unenforceability of any patent or pending patent application of the Company material to the business of the Company; or
          (xx) enter into any agreement, or otherwise become obligated, to do any of the foregoing.
          (b) Seller shall maintain or cause to be maintained in full force and effect the material insurance policies covering the Company until the Closing or shall replace them with reasonably comparable policies.
          (c) From the date hereof through the Closing, Seller shall use commercially reasonable efforts (including making any expenditures or payments to any third party) to obtain such Consents, approvals, authorizations and waivers from third parties that are necessary or required in connection with the execution, delivery and performance of this Agreement and the transactions contemplated hereby. If any Consent of a counterparty with respect to a Material Contract of the Company is not obtained at the Closing, then at the request of Buyer, Seller shall cooperate in any reasonable arrangement designed to obtain for Buyer the material economic benefits and burdens of such Material Contract, solely for a period of six (6) months following the Closing Date. Seller shall use commercially reasonable efforts to assist Buyer in providing notices and otherwise taking actions required to transfer or reissue any Governmental Authorization as a result of or in furtherance of the transactions contemplated by this Agreement and to cooperate with Buyer to provide information necessary to apply for the transfer or reissuance of such Governmental Authorization. Notwithstanding anything to the contrary in Section 6.5, Buyer and Seller shall, after reasonable prior notice to and consultation with the other Party, be permitted to provide confidential or proprietary information of the other Party to Governmental Authorities to the extent necessary to transfer or reissue any Governmental Authorization.
          (d) Nothing contained in this Agreement is intended to give Buyer, directly or indirectly, the right to control or direct the operations of the Company prior to the Closing. Prior to the Closing, Seller shall exercise, consistent with the terms and conditions of this Agreement, complete control and supervision over the Company and its operations.
          (e) Seller shall, at Seller’s sole cost and expense, comply with and complete all requirements and obligations imposed by ISRA arising out of the transactions contemplated by this Agreement. Without limiting the generality of the forgoing, Seller shall make any filings, provide any documents and execute any agreements necessary to obtain any Consents and approvals that are necessary pursuant to ISRA for the consummation of the transactions contemplated hereby. In the event that documentation confirming the completion of all applicable ISRA requirements, such as a Response Action Outcome (as defined in ISRA), is not received prior to Closing, Seller shall submit a Remediation Certification (as defined in ISRA) to NJDEP and post any required financial assurance necessary to allow the Closing to occur prior to the completion of Seller’s remaining ISRA obligations. Seller shall then

46


 

promptly and expeditiously complete all applicable ISRA requirements, including any assessments, investigation, or remediation that may be required. Seller may, at its option, elect to complete its ISRA obligations through the use of institutional or engineering controls, such as a deed notice or other restriction on future non-industrial or commercial use of the properties, provided that such controls or use restrictions must (i) be reasonably consistent with the current use of the properties immediately prior to Closing; (ii) not entail material continuing operation or maintenance obligations; (iii) not materially interfere with the continued non-residential use of the subject property; and (iv) with respect to any Leased Real Property, is acceptable to the owner of such Leased Real Property. Buyer shall cooperate with Seller and, after the Closing, shall cause the Company to cooperate with Seller with regard to completion of Seller’s ISRA obligations hereunder including, (A) upon reasonable advance request of Seller, providing Seller reasonable access to the relevant Company Real Property, personnel, records and utility services; (B) taking commercially reasonable actions to not unreasonably interfere with Seller’s ISRA investigations or remediation activities; (C) consenting to the implementation of reasonable institutional or engineering controls and use restrictions consistent with this paragraph; and (D) not taking actions (or failing to act) so as to knowingly exacerbate any existing environmental conditions, create new environmental conditions or otherwise increase the cost of Seller’s ISRA investigation or remediation activities. In completing its obligations, Seller shall cooperate with Buyer, including: (I) Seller shall commence and perform its actions promptly and without delay; (II) Seller shall not unreasonably interfere with Buyer’s operations at the Company Real Property; (III) Seller shall keep Buyer apprised of its actions and shall share draft and final copies of reports and filings; and (IV) Seller shall permit Buyer to reasonably consult with Seller and Seller’s Licensed Site Remediation Professional, who shall in good faith take into consideration the comments of Buyer. Seller shall indemnify Buyer with respect to any Losses relating to or arising from the activities of Seller or its agents or contractors related to its obligations as set forth in this Section 6.3(e).
     6.4 Employee Matters.
          (a) Until the first anniversary of the Closing Date, Buyer shall provide to each Company employee rates of base salary or wages and annual bonus opportunities, benefits and benefit plans, programs and policies (including severance benefits, medical and welfare plans) that are substantially comparable in the aggregate to those provided by Buyer to similarly situated employees of Buyer immediately prior to the Closing (other than equity or equity-related benefits, any defined benefit pension plan, or any nonqualified deferred compensation plan or arrangement).
          (b) Except as otherwise provided in this Section 6.4, as of the Closing Date, the Seller and the Company shall take such action as is necessary such that the Company shall cease being a “participating employer” and shall cease any co-sponsorship and participation in each Benefit Plan that is not a Company Benefit Plan (each such Benefit Plan being a “Seller Plan”). The Company shall have no further Liability and the Seller shall retain all Liabilities for Claims incurred under any Seller Plan (as determined under the terms of the Seller Plans), whether such Claims are incurred prior to, on or after the Closing Date. Seller shall provide under the Seller Plans any continuation coverage required under Section 4980B of the Code, Part 6 of Title I of ERISA or applicable state Law (“COBRA”) to each “qualified beneficiary”

47


 

as that term is defined in COBRA whose first “qualifying event” (as defined in COBRA) occurs on or prior to the Closing Date.
          (c) With respect to each employee benefit plan of Buyer or any Subsidiary thereof (each a “Buyer Plan”), in which Company employees subsequently participate, for purposes of determining vesting and entitlement to benefits, including for severance benefits and vacation entitlement, service with the Company (or predecessor employers thereof) shall be treated as service with the Person providing such Buyer Plan to the extent such service was taken into account under any substantially similar plan in which any such Company participated immediately prior to the Closing Date; provided, that such service shall not be recognized to the extent that such recognition would result in a duplication of benefits. To the extent permitted by each Buyer Plan, such Buyer Plan shall waive pre-existing condition limitations and waiting periods with respect to participation and coverage requirements to the same extent such limitations or waiting periods were inapplicable to, or had been satisfied by, such Company employee immediately prior to the Closing under the analogous Benefit Plan in which such Company employee participated. To the extent permitted by each Buyer Plan, Company employees shall be given credit for amounts paid under a corresponding Benefit Plan during the plan year in which the Closing occurs for purposes of applying deductibles, co-payments and out-of-pocket maximums as though such amounts had been paid in accordance with the terms and conditions of such Buyer Plan for the plan year in which the Closing occurs.
          (d) Nothing in this Section 6.4 shall create any third party beneficiary right in any Person other than the Parties, including any current or former Company employee, any participant in any Benefit Plan or Buyer Plan, or any dependent or beneficiary thereof, or any right to continued employment with Buyer or any of its respective Affiliates. Nothing in this Section 6.4 shall constitute an amendment to any Benefit Plan, Buyer Plan or any other plan or arrangement covering Company employees and nothing in this Section 6.4 shall limit the ability of Buyer or its Affiliates from amending the terms of, or terminating, any Benefit Plan, Buyer Plan or any other plan or arrangement covering Company employees pursuant to the terms of such plan or arrangement. The Company and Buyer shall each cooperate with the other and shall provide to the other such documentation, information and assistance as is reasonably necessary to effect the provisions of this Section 6.4.
          (e) As of the Closing Date, any separation benefits or severance plans maintained by the Seller or the Company covering or otherwise applicable to any active employees of the Company (which such separation benefits or severance plans are listed on Section 6.4(e) of the Seller Disclosure Schedule) shall be assumed and adopted by Buyer pursuant to this Agreement, without any further action on the part of the Parties, it being understood and agreed that nothing in this Agreement shall limit the ability of Buyer or its Affiliates from amending the terms of, or terminating, any such plan, program or arrangement pursuant to the terms of such plan, program or arrangement.
          (f) As of the Closing Date, (i) any employment agreement by and between Seller or the Company and any active employee of the Company (all of such employment agreements are listed on Section 6.4(f) of the Seller Disclosure Schedule) shall be assumed and adopted by Buyer pursuant to this Agreement, without any further action on the part of the Parties and (ii) any employment agreement by and between any Seller employee who performs

48


 

functions for and provides substantially all services to the Company (all of such employment agreements are listed on Section 6.4(f) of the Seller Disclosure Schedule) shall be assigned to the Company immediately prior to Closing and such employment agreement shall be assumed and adopted by Buyer pursuant to this Agreement, without any further action on the part of the Parties; provided, further, that with regard to such employment agreement contemplated by this Section 6.4(f), the definition of “Company” shall include any successors of the Company.
     6.5 Confidentiality.
          (a) Each Party agrees that it shall not use any Confidential Information of any other Party or its Affiliates for any purpose other than in connection with the consummation of the transactions contemplated by this Agreement, whether or not consummated. The receiving Party will safeguard the Confidential Information against disclosure by employing the same means to protect the Confidential Information as it uses to protect its own non-public, confidential or proprietary information. Each Party further agrees that it shall not divulge any such Confidential Information to any Person except (i) to its employees, agents, lenders, financial and other advisors and Representatives to the extent required in connection with the transactions contemplated by this Agreement, (ii) to the extent provided in the next sentence, as required to comply with deposition, interrogatory, request for documents, subpoena, civil investigative demand or similar process and (iii) as otherwise agreed to by the Parties in writing. In the event that a Party becomes legally compelled (by deposition, interrogatory, request for documents, subpoena, civil investigative demand or similar process) to disclose any of the Confidential Information, such Party shall (to the extent permitted by applicable Law) give the other Party prompt prior written notice of such requirement so that they may seek a protective order or other appropriate remedy and/or waive compliance with the terms of this Section 6.5. In the event that such protective order or other remedy is not obtained, or that the Party waives compliance with the terms of this Section 6.5, the receiving Party agrees to provide only that limited portion of the Confidential Information that it is advised by counsel is legally required and to exercise reasonable best efforts to obtain assurance that confidential treatment will be accorded such Confidential Information. Each Party shall inform its employees, agents, lenders, financial and other advisors and Representatives of the confidential nature of such information and the obligation to keep such information confidential, and shall take such other action as shall be reasonably required to cause such information to be kept confidential. For purposes of this Agreement, “Confidential Information” shall mean any non-public, confidential or proprietary information, including any information relating to any Party or its Affiliates’ properties or operations; provided, however, that Confidential Information shall not include any information if:
          (i) such information at the time of the disclosure or thereafter is generally available to the public (other than as a result of a disclosure by the receiving Party in violation of its confidentiality obligations set forth in this Section 6.5);
          (ii) such information was available to the receiving Party on a non-confidential basis from a source other than the other Party; provided, however that such source was not known by the receiving Party to be bound by a confidentiality agreement or a duty of confidentiality that protected the Confidential Information; or

49


 

          (iii) such information has been independently acquired or developed without use of Confidential Information by the receiving Party without violating any of its confidentiality obligations hereunder.
          (b) In the event that this Agreement is terminated, if requested by any Party, the other Party shall either promptly return or destroy the Confidential Information and all copies or other reproductions thereof, and all letters, notes and reports thereof, and all other materials, derived from the Confidential Information which are in such Party’s control, provided that each Party (i) may retain any Confidential Information contained in an archived computer system backup in accordance with such Party’s security and/or disaster recovery procedures and (ii) may retains copies of any Confidential Information prepared for archival or record retention purposes, where in each case, such information will remain subject to the provisions of this Section 6.5. The receiving Party agrees to represent in writing to the other Party that it has complied with the provisions of this paragraph.
          (c) Notwithstanding the foregoing, following Closing, (i) Buyer shall not be prohibited from disclosing to any Person any information relating to the Company, its business or any Assets and (ii) with respect to Seller, the confidentiality obligations set forth in Section 6.5 shall apply to any Confidential Information that Seller has that relates to the Company, its business or any Assets.
     6.6 Public Announcements. Except to the extent otherwise required by applicable Law or the rules and regulations of each stock exchange upon which the securities of a Party (or an Affiliate of such Party) are listed (and then only after consultation with Buyer or Seller, as applicable), none of the Parties will issue any press release or make any other public announcements concerning the transactions contemplated hereby or the contents of this Agreement without the prior written consent of the other Parties. If and to the extent that the terms set forth in this Section 6.6 conflict with the terms of Section 6.5, the terms set forth in this Section 6.6 shall control.
     6.7 No Solicitation; Other Offers. From the date hereof until the Closing, Seller, its Subsidiaries and Affiliates shall not, and shall cause each of their respective Subsidiaries, Affiliates, partners, members, officers, directors, employees, agents, advisors and other Representatives not to, directly or indirectly, (a) solicit, initiate, encourage any inquiries or proposals for, or enter into, participate in, continue or resume any discussions or negotiations with respect to, or enter into any agreement with respect to, any acquisition in any form, directly or indirectly, of the Company or any of its material Assets (including by way of merger, consolidation, sale, exchange or other disposition of Assets or Equity Interests or any business combination, recapitalization, liquidation, dissolution or other similar transaction) or (b) furnish or cause to be furnished any non-public information or confidential information concerning the Company, or otherwise cooperate with, assist, facilitate or encourage any effort or attempt by another Person (other than Buyer) to do or seek any transaction referred to in clause (a). Seller shall promptly notify Buyer in writing of any inquiry, proposal or offer relating to any transaction referred to in clause (a) above that is received by Seller, its Affiliates or any of their respective Representatives. Seller shall not release any third party from the confidentiality and standstill provisions of any Contract to which Seller or any of its Affiliates is a party and which

50


 

relates to the Company, its business or any Assets. Seller shall be responsible for any breach of this Section 6.7 by any of its Affiliates.
     6.8 Non-Competition; Non-Solicitation.
          (a) Until the fifth anniversary of the Closing Date (the “Non-Competition Period”), Seller shall not, and shall cause each of its Subsidiaries and any other Person in which it holds, directly or indirectly, controlling Equity Interests (such Persons, including their respective successors or assigns, are collectively referred to herein as the “Restricted Parties”), not to, directly or indirectly, form, own, manage, operate, join, control or participate (whether as a partner, agent, representative, or otherwise) in the ownership, management, operation or control of any Person in any territory in which the Company operates immediately prior to Closing or has taken reasonable measures as of the Closing Date to begin operating (the “Territory”), that, directly or indirectly competes with the business of the Company as it shall exist immediately prior to the Closing Date (including only changes or expansions in the business of the Company or the products sold or distributed by the Company that are expressly contemplated as of the Closing (including, for the avoidance of doubt, the Alternate Site Products)) (a “Competing Business”). In addition, during the Non-Competition Period, neither Seller nor any Restricted Party shall have, without Buyer’s prior written consent, any direct or indirect equity ownership in any such Person, other than as an owner of 2% or less of the outstanding stock of a publicly traded corporation. For the avoidance of doubt, Seller and the Restricted Parties shall not be restricted by the provisions of this Section 6.8 from acquiring (whether through a purchase of stock or assets, through a merger or consolidation, or otherwise) any Person that derives less than ten percent (10%) and less than $25,000,000 of its gross revenues (as measured from the conclusion of each of such Person’s last three completed fiscal years) from any Competing Businesses; provided, however, that following an acquisition permitted by this sentence, if such acquired Person derives more than twelve percent (12%) or more than $30,000,000 of its gross revenues from any Competing Businesses during any fiscal year that ends during the Non-Competition Period, Seller or such Restricted Party (as applicable) shall promptly provide written notice to Buyer of such fact and shall divest, as soon as reasonably practicable (but in any event within twelve months of providing such notice), a portion of the business of such Person that engages in Competing Businesses such that less than twelve percent (12%) and less than $30,000,000 of such Person’s gross revenues would be derived from Competing Businesses during the remainder of the Non-Competition Period. Seller shall keep Buyer informed, on a reasonably current basis and in reasonable detail, of the status of Seller’s efforts to divest such business (or portion thereof) in accordance with the preceding proviso and Buyer shall have the right to participate as a potential purchaser in the sale process for such business (or portion thereof) on terms at least as favorable to those being offered to other participants in the sale process.
          (b) Until the third anniversary of the Closing Date, Seller shall not, and shall cause each of the Restricted Parties not to, directly or indirectly, for itself or on behalf of any Person, (i) solicit for employment or hire any Company employee; provided, however that any such employee may seek employment with the applicable Person in response to a general advertisement not directed at such employee and the applicable Person may hire any employee who responds to such general advertisement; (ii) approach any supplier or licensee of the Company with respect to products or services it provided to the Company at any time during the

51


 

twelve-month period prior to the Closing with the intention of harming the business or operations of the Company by causing such Person to decrease or cease doing business with the Company; or (iii) approach any Person who is a customer of the Company at any time during the twelve-month period prior to the Closing with the intention of harming the business or operations of the Company by causing such Person to purchase the products of any business competitive with the Company.
          (c) Seller acknowledges that the provisions set forth in this Section 6.8 are an integral part of the success of the Company throughout the Territory. If, on or after the Closing Date, Seller or any Restricted Party utilizes its reputation and goodwill in competition with Buyer, Buyer will be deprived of the benefits it has bargained for pursuant to this Agreement. In the event that the agreements in this Section 6.8 shall be determined by any court of competent jurisdiction to be unenforceable by reason of extending for too great a time or over too great a geographical area or by reason of it being too extensive in any other respect, it shall be interpreted to extend only over the maximum period of time for which it may be enforceable and/or over the maximum geographical area as to which it may be enforceable and/or to the maximum extent in all other respects as to which it may be enforceable, all as determined by such court in such action.
          (d) If Seller or any Restricted Party breaches or threatens to commit a breach of any of the restrictive covenants set forth in this Section 6.8, then the Company and Buyer shall each have the following rights and remedies against Seller or such Restricted Party, each of which shall be independent of the others and severally enforceable, and each of the following rights and remedies is in addition to, and not in lieu of, any other rights and remedies otherwise available to any of them at Law or in equity: the right and remedy to have the restrictive covenants in this Section 6.8 specifically enforced against the Seller or such Restricted Party, including temporary restraining orders and injunctions by any court of competent jurisdiction, it being agreed by Seller that any breach or threatened breach by Seller or any Restricted Party of this Section 6.8 would cause irreparable injury to the Company and Buyer and that money damages would not provide an adequate remedy to the Company or Buyer.
          (e) Each of Seller and Buyer intends that the covenants set forth in Sections 6.8(a) and 6.8(b) shall be deemed to be a series of separate covenants, one for each county or province of each and every state, territory or jurisdiction within the Territory, and one for each month of the time periods covered by such covenants.
          (f) Seller hereby agrees that in the event a court of competent jurisdiction declares there has been a breach by Seller or any Restricted Party of Section 6.8(a) or Section 6.8(b), the term of any such covenant so breached shall be automatically extended beyond its intended expiration for a period of time equal to the duration of such breach.
          (g) Seller shall be responsible for any breach of this Section 6.8 by any of its Subsidiaries or any other Person in which Seller holds, directly or indirectly, controlling Equity Interests.
     6.9 Intercompany Arrangements. Prior to the Closing, all Contracts of any kind (except for Contracts for the payment of wages, salaries, bonuses or other compensation to

52


 

officers or directors of the Company for services performed in the ordinary course of business (all of which are set forth on Section 4.23 of the Seller Disclosure Schedule)) between Seller, any of Seller’s Subsidiaries, any other Person in which Seller holds, directly or indirectly, controlling Equity Interests (other than the Company) or any of their respective directors or officers, on the one hand, and the Company, on the other hand, will be terminated without any payment by, Liability of or cost to Buyer or any Affiliate thereof, including the Company, following the Closing. A copy of any fully executed termination agreement entered into in accordance with the preceding sentence will be provided by Seller to Buyer prior to or at the Closing. Prior to the Closing, Seller shall settle in Cash all receivables or payables, loans or other amounts due or owed which are existing and outstanding at any time prior to the Closing between Seller, any of Seller’s Subsidiaries, any other Person in which Seller holds, directly or indirectly, controlling Equity Interests (other than the Company) or any of their respective directors or officers, on the one hand, and the Company, on the other hand.
     6.10 Insurance. Buyer shall be solely responsible for providing insurance to the Company for any event or occurrence after the Closing. Without limiting the rights of Buyer set forth elsewhere in this Agreement, if any Claims may reasonably be made, or if Losses have occurred prior to the Closing Date that relate to the Company, and such Claims may be made against insurance policies retained by Seller or its Affiliates, then Seller (on behalf of itself and its Affiliates) shall, at Buyer’s request and at Buyer’s sole cost and expense, use its reasonable best efforts in an effort to permit Buyer (after the Closing Date and in cooperation with Seller) to file, notice and otherwise continue to pursue such Claims and recover proceeds under the terms of such policies, and, subject to all of the foregoing, Seller (on behalf of itself and its Affiliates) agrees (at Buyer’s sole cost and expense) to otherwise reasonably cooperate with Buyer or its Affiliates to make the benefits of any such insurance policies available to Buyer or its Affiliates.
     6.11 Delivery of Updated Financial Information. From the date of this Agreement until the Closing, Seller will deliver to Buyer the form of unaudited financial statements of the Company set forth in Section 6.11 of the Seller Disclosure Schedule for each fiscal month ended after January 2, 2010 (collectively, the “Interim Financial Information”) within twenty (20) days after the conclusion of such month. The Interim Financial Information will be prepared in a manner consistent with the past practice of the Company with respect to such monthly financial statements.
     6.12 Cooperation; Financial Reporting; Transition Services.
          (a) Buyer agrees to furnish or cause to be furnished, upon written request, information and assistance of employees relating to the pre-Closing operation of the business of the Company as is necessary in the reasonable judgment of Seller in order for Seller (i) to satisfy on a timely basis its financial reporting obligations related to the Company pursuant to the Exchange Act until the date of filing of Seller’s 10-K for the 2010 fiscal year of Seller and (ii) from the date of filing of Seller’s 10-K for the 2010 fiscal year of Seller until two (2) years from such date, to satisfy any other legitimate legal obligation (as determined by Seller in good faith) or financial reporting obligation of Seller relating to the pre-Closing operation of the business of the Company and identified to Buyer in writing. The obligations of Buyer pursuant to clause (i) above shall include access at reasonable times within normal business hours to all books and records of the Company relating to the pre-Closing operation of the business of the

53


 

Company as may be reasonably requested by Seller and the assistance of all personnel of the Company, who, in the ordinary course of business of the Company as of the date hereof, perform services or otherwise aid Seller with respect to such reporting obligations; provided, that in no event shall such access or assistance unreasonably interfere with the operation of the Company’s business or the duties of such personnel to the Company. The obligations of Buyer pursuant to clause (ii) above shall include access at reasonable times within normal business hours to the specific books and records of the Company required for the purpose specified by Seller in its request for such services and the assistance of certain personnel of the Company to be mutually agreed between Buyer and Seller; provided, that in no event shall such access or assistance unreasonably interfere with the operation of the Company’s business or the duties of such personnel to the Company. Buyer shall be obligated to provide the services set forth in clauses (i) and (ii) at a cost to Seller consistent with the hourly rates of the employees performing such services (or, if such employees are salaried employees, at a reasonable approximation of such employee’s per hour salary) and Seller shall reimburse Buyer for all out-of-pocket expenses incurred by Buyer in providing such services. For the avoidance of doubt, cooperation obligations related to Taxes are addressed solely in Section 10.4. In no event shall Buyer or the Company have any Liability in respect of any reasonable act or omission of any employee of the Company with respect to the performance of the services contemplated by this Section 6.12. All Confidential Information of either Party of which the other Party becomes aware during the provision of the services contemplated by this Section 6.12 shall be treated in accordance with Section 6.5. Notwithstanding anything to the contrary in this Agreement, (A) Buyer shall not be required to take any action pursuant to this Section 6.12 if there is a legitimate business reason for not taking such action, as determined in good faith by Buyer, and (B) Buyer need not supply Seller with any access or information which Buyer or any of its Affiliates is under a legal obligation not to supply.
          (b) During the period beginning on the date hereof and ending on the Closing Date, the Parties will work in good faith and reasonably cooperate with each other to negotiate and finalize a Transition Services Agreement (the “Transition Services Agreement”). The Parties acknowledge and agree that (i) the term of the services provided under the Transition Services Agreement will be for 90 days after Closing, unless mutually extended by the Parties, (ii) the price for the services provided under the Transition Services Agreement will be at cost and Buyer shall reimburse Seller for all out-of-pocket expenses incurred by Seller in providing such services, (iii) the services covered by the Transition Services Agreement will consist of: employee benefit plan administration, payroll administration, transfer of 401(k) loans, separation of telephony systems, separation of network services, and separation of Microsoft contracts, (iv) in no event shall Seller have any Liability in respect of any reasonable act or omission of any employee of Seller with respect to the performance of the services contemplated by the Transition Services Agreement and (v) during the period covered by the Transition Services Agreement, Buyer or its Affiliates will not undertake any reduction in force or other material number of terminations (other than any terminations for cause) with respect to the employees of the Company. The Parties agree to consider in good faith any changes to the terms described in the foregoing sentence due to any change in facts or circumstances discovered after the date hereof.
     6.13 Notification of Certain Matters. Each of Seller and Buyer shall give reasonably prompt notice to the other Party of (i) the occurrence or non-occurrence of any event the

54


 

occurrence or non-occurrence of which would or would be reasonably likely to cause any representation or warranty of the applicable Party contained herein to be untrue or inaccurate in any material respect at any time at or prior to the Closing, or which, individually or in the aggregate, could result in a Material Adverse Effect, (ii) any event which would reasonably be expected to cause any of the conditions in Article VII or Article VIII, as applicable, not to be satisfied, and (iii) any material failure of the applicable Party to comply with or satisfy in a timely manner any covenant, condition or agreement to be complied with or satisfied by such Party hereunder. The delivery of any notice pursuant to this Section 6.13 shall not be deemed to (A) modify the representations, warranties, covenants or agreements hereunder of the Party delivering such notice, or any of the Disclosures Schedules, or (B) cure or prevent any misrepresentation, inaccuracy, untruth or breach of any representation, warranty, covenant or agreement set forth in this Agreement or failure to satisfy any condition set forth in Article VII or Article VIII, as applicable; provided, however, that a failure to comply with this Section 6.13 prior to the Closing Date in and of itself will not constitute the failure of the condition set forth in Section 7.2 or Section 8.2, as the case may be, to be satisfied unless (i) such failure materially prejudices another Party’s ability to exercise its rights or remedies hereunder prior to the Closing or (ii) the underlying event would independently result in the failure of the condition set forth in Section 7.1 or Section 8.1, as the case may be, to be satisfied.
     6.14 Title Insurance and Surveys. With respect to the Owned Real Property, Seller and the Company shall use commercially reasonable efforts to assist Buyer (at Buyer’s sole cost and expense) in obtaining title insurance policies and surveys in form and substance satisfactory to Buyer, including removing from title any Encumbrances (other than Permitted Encumbrances). The Company shall provide Buyer’s title company with any affidavit, indemnity or other assurances reasonably requested by such title company in order to issue such title insurance policies.
     6.15 FDA Matters.
          (a) During the period beginning on the date hereof and ending on the Closing Date, Seller shall take, or cause to be taken, all actions, and to do, or cause to be done, all activities reasonably necessary to (i) initiate and continue the remediation of all outstanding FDA observations and findings with respect to the Company’s regulatory compliance, consistent with the Company’s operating plan for fiscal year 2010 (based on the April 2010 version of such plan) as it relates to remediation actions, (ii) promptly address all new FDA observations or findings in the event of an FDA communication with, audit of or inspection of the Company, (iii) cooperate with the FDA in the event of any threatened enforcement Action against the Company and address promptly any matters identified by the FDA to cause such enforcement Action not to be initiated, (iv) if an FDA enforcement Action is initiated against the Company, take prompt action to remediate any new or outstanding FDA observations and findings and seek withdrawal or mitigation of any such Action, (v) provide prompt notice to Buyer as to any threatened or initiated enforcement Action against the Company, including information as to the scope and nature of such Action and any planned response, and (vi) reasonably consider any proposals made by Buyer in connection with any such matters. On a weekly basis, Seller shall provide updates to Buyer on the status of all such remediation efforts, including with respect to any meetings or other communications with the FDA. Any costs or

55


 

expenses incurred by the Company in connection with complying with this Section 6.15 shall be borne by Seller.
  (b)   From and after the Closing until the date that is three (3) years from the Closing Date, in connection with any Losses arising out of or resulting from (directly or indirectly) the Known FDA Matters, Seller shall be responsible for (and shall pay) eighty percent (80%) of all such Losses and Buyer shall be responsible for (and shall pay) twenty percent (20%) of all such Losses; provided, however, that (i) the foregoing covenant (the “FDA Cost-Sharing Covenant”) shall only apply once the aggregate amount of Losses arising out of or resulting from (directly or indirectly) the Known FDA Matters exceeds $2,000,000 (and Buyer shall be solely responsible for such first $2,000,000), and (ii) the aggregate amount required to be paid by Seller pursuant to the FDA Cost-Sharing Covenant shall not exceed an amount equal to $25,000,000 (which, for purposes of calculating this amount, (x) includes all amounts paid by Seller pursuant to its indemnification obligations under Section 9.2(a)(i) hereof which are subject to the limitations set forth in Section 9.3(a)(ii), (y) excludes the $2,000,000 threshold amount described in the foregoing clause (i), and (z) excludes the twenty percent (20%) of the amount of Losses that are not required to be paid by Seller pursuant to the FDA Cost-Sharing Covenant).
ARTICLE VII.
CONDITIONS TO SELLER’S OBLIGATIONS
          The obligations of Seller to consummate the transactions contemplated by this Agreement are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by Seller in writing to the extent allowed by applicable Law:
     7.1 Accuracy of Buyer’s Representations and Warranties.
          (a) The representations and warranties of Buyer contained in Sections 5.1, 5.2, and 5.6, in each case disregarding all qualifications contained therein relating to materiality or Material Adverse Effect, shall be true and correct in all material respects when made and on and as of the Closing Date with the same force and effect as though such representations and warranties had been made on the Closing Date.
          (b) The representations and warranties of Buyer contained in Article V (other than the representations and warranties contained in Sections 5.1, 5.2, and 5.6), in each case disregarding all qualifications contained therein relating to materiality or Material Adverse Effect, shall be true and correct when made and on and as of the Closing Date with the same force and effect as though such representations and warranties had been made on the Closing Date, except to the extent that the failure of such representations and warranties to be true and correct would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse Effect on Buyer.
          (c) Seller shall have received a certificate from Buyer signed by a duly authorized officer of Buyer confirming the foregoing clauses (a) and (b) as of the Closing Date.

56


 

     7.2 Covenants. Buyer shall have performed and satisfied in all material respects the agreements and covenants required hereby to be performed by it prior to or on the Closing Date. Seller shall have received a certificate signed by a duly authorized officer of Buyer confirming the foregoing as of the Closing Date.
     7.3 No Laws or Governmental Orders. No preliminary or permanent injunction or other Governmental Order which prevents or prohibits the consummation of the transactions contemplated hereby shall have been issued and remain in effect (each Party agreeing to use its reasonable efforts to have any such injunction or Governmental Order lifted) and no Law shall have been enacted which prevents or prohibits the consummation of the transactions contemplated hereby.
     7.4 HSR Waiting Period. The applicable waiting period, including any extension thereof, under the HSR Act shall have expired or been terminated.
     7.5 Deliveries. Seller shall have received from Buyer each of the deliveries described in Section 3.3(b) hereof.
     7.6 No Actions. There shall be no Action pending by any Governmental Authority wherein an unfavorable Governmental Order would reasonably be expected to, (a) prohibit, enjoin or prevent consummation of the Closing or (b) cause any of the material transactions contemplated by this Agreement to be rescinded following the Closing.
     7.7 Austrian Antitrust Filing. Buyer and Seller shall have received written notice from the applicable Governmental Authority that the merger control requirements under the Austrian Cartel Act of 2005 have been satisfied.
ARTICLE VIII.
CONDITIONS TO BUYER’S OBLIGATIONS
          The obligations of Buyer to consummate the transactions contemplated by this Agreement are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by Buyer in writing to the extent allowed by applicable Law:
     8.1 Accuracy of Seller’s Representations and Warranties.
          (a) The representations and warranties of Seller contained in Sections 4.1 (other than the last sentence of such Section), 4.5 and 4.8 shall be true and correct when made and on and as of the Closing Date with the same force and effect as though such representations and warranties had been made on the Closing Date (except for such representations and warranties which by their express provisions are made as of an earlier date, in which case they shall be true and correct as of such date).
          (b) The representations and warranties of Seller contained in the last sentence of Section 4.1, the first sentence of Section 4.2 and the first sentence of Section 4.7 and Sections 4.3 and 4.20, in each case disregarding all qualifications contained therein relating to materiality or Material Adverse Effect, shall be true and correct in all material respects when made and on

57


 

and as of the Closing Date with the same force and effect as though such representations and warranties had been made on the Closing Date (except for such representations and warranties which by their express provisions are made as of an earlier date, in which case they shall be true and correct in all material respects as of such date).
          (c) The representations and warranties of Seller contained in Article IV (other than the representations and warranties contained in the first sentence of Section 4.2 and the first sentence of Section 4.7 and the representations and warranties contained in Sections 4.1, 4.3, 4.5, 4.8 and 4.20), in each case disregarding all qualifications contained therein relating to materiality or Material Adverse Effect, shall be true and correct when made and on and as of the Closing Date with the same force and effect as though such representations and warranties had been made on the Closing Date (except for such representations and warranties which by their express provisions are made as of an earlier date, in which case they shall be true and correct as of such date), except to the extent that the failure of such representations and warranties to be true and correct would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse Effect. Notwithstanding the foregoing, Buyer acknowledges and agrees that any breach of the first sentence of Section 4.24(b) caused by the announcement of the transactions contemplated by this Agreement shall not constitute a breach of the first sentence of Section 4.24(b) for the purposes of determining whether the condition set forth in this Section 8.1(c) has been satisfied.
          (d) Buyer shall have received a certificate from Seller signed by a duly authorized officer of Seller confirming the foregoing clauses (a), (b) and (c) as of the Closing Date.
     8.2 Covenants. Seller shall have performed and satisfied in all material respects the agreements and covenants required hereby to be performed by it prior to or on the Closing Date. Buyer shall have received a certificate from Seller signed by a duly authorized officer of Seller confirming the foregoing as of the Closing Date.
     8.3 No Law or Governmental Orders. No preliminary or permanent injunction or other Governmental Order which prevents or prohibits the consummation of the transactions contemplated hereby shall have been issued and remain in effect (each Party agreeing to use its reasonable efforts to have any such injunction or Governmental Order lifted) and no Law shall have been enacted which prevents or prohibits the consummation of the transactions contemplated hereby.
     8.4 HSR Waiting Period. The applicable waiting period, including any extension thereof, under the HSR Act shall have expired or been terminated.
     8.5 Deliveries. Buyer shall have received from Seller each of the deliveries described in Section 3.3(a) hereof, other than Section 3.3(a)(ix).
     8.6 No Actions. There shall be no Action pending by any Governmental Authority (a) wherein an unfavorable Governmental Order or consent agreement would reasonably be expected to (i) prohibit, enjoin or prevent consummation of the Closing or (ii) cause any of the material transactions contemplated by this Agreement to be rescinded following the Closing or

58


 

(b) which would reasonably be expected to result in any material injunction or material seizure or any material product recall, material market withdrawal, material manufacturing delay or material product discontinuation, in each case relating to material products of the Company.
     8.7 Material Adverse Effect. Since the date of this Agreement, no event, change, development or effect shall have occurred that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect. Buyer shall have received a certificate from Seller signed by a duly authorized officer of Seller confirming the foregoing as of the Closing Date.
     8.8 Austrian Antitrust Filing. Buyer and Seller shall have received written notice from the applicable Governmental Authority that the merger control requirements under the Austrian Cartel Act of 2005 have been satisfied.
     8.9 FDA Matters. No Action shall have been initiated or, to the Knowledge of Seller, threatened by the FDA against the Company where such Action would reasonably be expected to result in criminal penalties or material civil monetary penalties.
ARTICLE IX.
SURVIVAL AND INDEMNIFICATION
     9.1 Survival.
          (a) Each and every representation and warranty contained in this Agreement (other than the Fundamental Representations and Warranties and the Specified Representations and Warranties) shall survive the Closing Date until the date that is eighteen (18) months from the Closing Date and then expire. Each Specified Representation and Warranty shall survive the Closing Date until the third anniversary of the Closing Date and then expire. Each Fundamental Representation and Warranty shall survive the Closing Date until, and will expire when, the longest applicable statute of limitation applicable to such Fundamental Representation and Warranty, or underlying Claims that may constitute a breach thereof, expires.
          (b) Each and every covenant contained in Article VI of this Agreement (other than the covenants contained in Section 6.3, Section 6.6, Section 6.9 and Section 6.15 and the covenants contained in this Agreement which by their terms are to be performed (in whole or in part) by the Parties following the Closing (collectively, the “Surviving Covenants”)) shall expire with, and be terminated by, the Closing; and none of Seller, Buyer or any Representative or Affiliate of any of them shall have any Liability whatsoever with respect to any such covenant. Each Surviving Covenant shall survive the Closing Date until, and will expire when, the statute of limitation applicable to such covenant expires.
          (c) Any representation, warranty or covenant in respect of which indemnity may be sought under this Article IX, and the indemnity with respect thereto, shall survive the time at which it would otherwise terminate pursuant to this Section 9.1 if written notice of the Claim giving rise to such right or potential right of indemnity shall have been given to the party against whom such indemnity may be sought prior to such time and, in any such case, such representation, warranty or covenant shall survive until any Claim (and any Claim arising out of

59


 

similar facts and circumstances) for indemnity related to such inaccuracy or breach or potential inaccuracy or breach is settled or fully resolved.
     9.2 Indemnification.
          (a) From and after the Closing, Seller shall indemnify, defend (subject to Section 9.2(c)) and hold harmless the Buyer Indemnified Parties from and against any and all Losses incurred, suffered or sustained by any Buyer Indemnified Party in connection with, arising out of or resulting from (directly or indirectly): (i) any breach of any representation or warranty made by Seller in Article IV, as if such representation or warranty had been made on and as of the date of this Agreement and as of the Closing Date (except for any such representation or warranty that addresses matters only as of a particular date, which need be accurate only as of such date) and any Third Party Claim alleging facts that, if true, would constitute such a breach of any representation or warranty; (ii) any breach of any Surviving Covenant by Seller; (iii) any Pre-Closing Taxes; and (iv) any Claim by any Person who was an officer, director or stockholder of the Company at any time prior to the Closing, which Claim is made in such capacity, to the extent such Claim does not arise from any action of Buyer Indemnified Parties after the Closing.
          (b) From and after the Closing, Buyer shall indemnify, defend (subject to Section 9.2(c)) and hold harmless the Seller Indemnified Parties from and against any and all Losses incurred, suffered or sustained by any Seller Indemnified Party in connection with, arising out of or resulting from (directly or indirectly): (i) any breach of any representation or warranty made by Buyer in Article V, as if such representation or warranty had been made on and as of the date of this Agreement and as of the Closing Date (except for any such representation or warranty that addresses matters only as of a particular date, which need be accurate only as of such date) and any Third Party Claim alleging facts that, if true, would constitute such a breach of any representation or warranty; and (ii) any breach of any Surviving Covenant by Buyer.
          (c) If a Claim for Losses is to be made by a Party entitled to indemnification hereunder with respect to any Claim or other assertion of Liability by a third party (a “Third Party Claim”), the Party claiming such indemnification shall give written notice (a “Claim Notice”) to the indemnifying Party as soon as reasonably practicable after the Party entitled to indemnification becomes aware of any fact, condition or event which may give rise to Losses for which indemnification may be sought under this Section 9.2 with respect to any Third Party Claim; provided, however, if any Action is filed against any Party entitled to the benefit of and seeking indemnity hereunder for a Third Party Claim, the applicable Claim Notice shall be given to the indemnifying Party within twenty (20) Business Days after the service of the citation or summons (the “Notice Period”). Notwithstanding the foregoing, the failure of any indemnified Party to give timely notice hereunder shall not affect rights to indemnification hereunder, except and only to the extent that the indemnifying Party is actually and materially prejudiced by such failure. The Parties understand and agree that the failure of the indemnified Party to so notify the indemnifying Party prior to settling any such Third Party Claim (whether by paying the Third Party Claim or executing a binding settlement agreement with respect thereto) shall constitute actual and material prejudice to the indemnifying Party’s ability to defend against such Third Party Claim; provided, that the indemnified Party is hereby

60


 

authorized (but not obligated) prior to and during the Notice Period to file any motion, answer or other pleading and to take any other action which the indemnified Party shall deem necessary or appropriate to protect the indemnified Party’s interests. After receiving a Claim Notice, the indemnifying Party shall be entitled, upon written notice to the indemnified Party, at its own cost, risk and expense, (i) to take control of the defense and investigation of such Action, (ii) to employ and engage attorneys of its own choice (reasonably acceptable to the indemnified Party) to handle and defend the same (unless the named Parties to such Action include both the indemnifying Party and the indemnified Party and the indemnified Party has been advised by counsel that (A) there may be one or more legal defenses available to such indemnified Party that are different from or additional to those available to the indemnifying Party or (B) there are issues that raise actual or likely conflicts of interest between the indemnifying Party and the indemnified Party, in which event the indemnified Party shall be entitled, at the indemnifying Party’s cost, risk and expense, to separate counsel of its own choosing) and (iii) to compromise or settle such Third Party Claim, which compromise or settlement shall be made only with the written consent of the indemnified Party, such consent not to be unreasonably withheld or delayed; provided, however, that the indemnifying Party shall not be entitled to assume control of such defense and shall pay the fees and expenses of counsel retained by the indemnified Party if (1) the indemnifying Party does not agree in writing to be fully responsible for all Losses relating to such Third Party Claim; (2) the Third Party Claim involves a Governmental Authority; (3) the Third Party Claim relates to or arises in connection with any criminal Action; or (4) the Third Party Claim seeks equitable relief or any other non-monetary remedy against the indemnified Party. In the event the indemnifying Party takes control of the defense and investigation of such a Claim, the indemnified Party may, at its own cost and expense, participate in the investigation, trial and defense of such Action and any appeal arising therefrom (it being understood that the indemnifying Party shall control such defense). If the indemnifying Party fails to assume the defense of such Third Party Claim within fifteen (15) Business Days after receipt of the Claim Notice, the indemnified Party against which such Third Party Claim has been asserted will (upon delivering notice to such effect to the indemnifying Party) have the right to undertake, at the indemnifying Party’s cost and expense, the defense, compromise or settlement of such Third Party Claim on behalf of and for the account and risk of the indemnifying Party. Any Third Party Claim the defense of which is assumed by an indemnified Party shall not be compromised or settled without the written consent of the indemnifying Party, which consent shall not be unreasonably withheld or delayed. In the event the indemnified Party assumes the defense of a Third Party Claim, the indemnified Party will keep the indemnifying Party reasonably informed of the progress of any such defense, compromise or settlement. The Parties shall cooperate in all reasonable respects with each other in the investigation, trial and defense of any Third Party Claim for Losses or Action and any appeal arising therefrom.
          (d) If an indemnified Party asserts a Claim which does not involve a Third Party Claim, the indemnified Party shall provide a Claim Notice to the indemnifying Party prior to the expiration of the relevant survival period specified in Section 9.1. If the indemnifying party does not notify the indemnified Party within twenty (20) Business Days of its receipt of the Claim Notice that the indemnifying Party disputes such Claim, the amount of such Claim shall be conclusively deemed a liability of the indemnifying Party hereunder. If the indemnifying Party makes an objection in writing (which such writing must include a reasonable description of the indemnifying Party’s basis for such objection(s)), the indemnified

61


 

Party shall have fifteen (15) Business Days to respond in a written statement to the objection(s). If after such fifteen (15) Business Day period there remains a dispute as to any such Claim, the Parties shall attempt in good faith for twenty (20) Business Days to agree upon the rights of the respective Parties with respect to such Claim. If the Parties should so agree, a memorandum setting forth such agreement shall be prepared and signed by both Parties. If such Parties shall not agree, an indemnified Party shall be entitled to initiate an Action and seek remedies as may be permitted under the terms of this Agreement.
          (e) In the event of payment in full by the indemnifying Party to the indemnified Party in connection with any Claim (an “Indemnified Claim”), the indemnifying Party shall be subrogated to and shall stand in the place of the indemnified Party as to any events or circumstances in respect of which the indemnified Party may have any right or Claim relating to such Indemnified Claim against any claimant or plaintiff asserting such Indemnified Claim or against any other Person. The indemnified Party shall cooperate with the indemnifying Party in a reasonable manner, and at the cost and expense of the indemnifying Party, in prosecuting any subrogated right or Claim.
          (f) The Parties shall reasonably cooperate with each other with respect to resolving any Claim or Liability with respect to which one Party is obligated to indemnify another Party hereunder, including, at the written request of, and at the sole cost and expense of, the indemnifying Party, using commercially reasonable efforts to mitigate any such Claim or Liability.
          (g) For purposes of determining whether there has been a breach of any representation or warranty contained in this Agreement, or the amount of any Loss related to a breach of any representation or warranty contained in this Agreement, the representations and warranties contained in this Agreement shall be considered without regard to any “material,” “Material Adverse Effect” or similar qualifications contained therein. The representations, warranties and covenants contained in this Agreement shall not be affected by any investigation, inquiry or examination made for or on behalf of any Party, or the knowledge of any Party of a breach of any representation, warranty or covenant by the other Party.
     9.3 Limitations on Indemnification.
          (a) Except as provided in the last sentence of this Section 9.3(a), notwithstanding anything to the contrary contained in this Agreement, (i) no indemnification under Section 9.2(a)(i) hereof shall be made by Seller and no indemnification under Section 9.2(b)(i) hereof shall be made by Buyer, and neither Seller nor Buyer shall have any Liability, respectively, to the other therefor, unless and until the aggregate amount of Losses subject to indemnification pursuant thereto and due the Party being indemnified shall exceed $1,250,000 (the “Threshold Amount”), and once the Threshold Amount is exceeded the indemnifying Party shall indemnify the indemnified Party, and shall be liable, only for the amount of any such Losses in excess of the Threshold Amount; (ii) the aggregate amount required to be paid by Seller pursuant to its indemnification obligations under Section 9.2(a)(i) hereof or by Buyer pursuant to its indemnification obligations under Section 9.2(b)(i) hereof shall not exceed an amount equal to $25,000,000 ((A) which amount, for the avoidance of doubt, excludes the Threshold Amount and (B) in the case of Seller, for purposes of calculating such amount,

62


 

includes any amounts paid by Seller pursuant to the FDA Cost-Sharing Covenant), and neither Party shall have any Liability to any indemnified Party for, and such indemnified Parties shall have no right to recover from Seller or Buyer, as the case may be, any amount of Losses which exceeds (and from and after the time such Losses exceed) such amount; and (iii) no indemnification under Section 9.2(a)(i) hereof shall be made by Seller and no indemnification under Section 9.2(b)(i) hereof shall be made by Buyer, and neither Seller nor Buyer shall have any Liability, respectively, to the other for any individual Claim or any Liability arising out of or resulting from a single action, event, occurrence or a set of circumstances, unless such individual Claim or such Liability arising out of or resulting from a single action, event, occurrence or a set of circumstances is greater than $37,500; provided, that in the case of clause (iii) above, any Claims or Liabilities resulting from similar facts or circumstances shall be aggregated for the purposes of determining whether such Claims or Liabilities are indemnifiable pursuant to such clause. The applicable indemnified Party shall be entitled to indemnification without regard to any of the provisions of this Section 9.3(a) with respect to indemnification obligations for Losses relating to Fundamental Representations and Warranties or Claims of fraud, intentional misrepresentation or willful breach of this Agreement (provided, however, that the aggregate Liability of Seller or Buyer pursuant to this Section 9.3(a) shall in no event exceed the Initial Cash Price, plus any Earnout Amounts paid to Seller pursuant to Section 2.3).
          (b)
          (i) To the extent that any Losses or Claim therefor which is subject to indemnification hereunder are covered by insurance held by any indemnified Party (an “Insured Loss”), such indemnified Party shall only be entitled to indemnification pursuant to Section 9.2 hereof with respect to the amount of Losses in excess of the net cash proceeds actually received by such indemnified Party pursuant to such insurance (after deducting the out-of-pocket costs and expenses incurred in connection with obtaining such proceeds, excluding incremental insurance premium costs). With respect to any Insured Loss, the applicable indemnified Party shall first use all commercially reasonable efforts to obtain the maximum recovery from the provider of such insurance and then, to the extent that the net cash proceeds received by such indemnified Party (after deducting the out-of-pocket costs and expenses incurred in connection with obtaining such proceeds, excluding incremental insurance premium costs) are less than the amount of the Losses indemnified hereunder, or if the indemnified Party is unable to promptly obtain full recovery from such provider, the indemnified Party shall be entitled to seek indemnification pursuant to Section 9.2 hereof with respect to the amount of the Losses that exceed such recovery, if any; provided, however, that if, following the receipt of any indemnity payments pursuant to Section 9.2 hereof, the indemnified Party obtains any insurance recovery from a third party insurance provider, with respect to such Losses, then such indemnified Party shall promptly pay over to the indemnifying Party (in proportion to their relative payments in respect of the underlying Loss) the amount of the net cash proceeds received by such indemnified Party pursuant to such insurance (after deducting the out-of-pocket costs and expenses incurred in connection with obtaining such proceeds, excluding incremental insurance premium costs) up to, but not in excess of, the amount of the indemnity payments made by the indemnifying Party pursuant to such Losses. The Parties agree that (i) no insurance company shall have any right of subrogation under this Section 9.3(b), (ii) this Section 9.3(b) is not for the benefit

63


 

of any third party insurance provider and (iii) this Section 9.3(b) shall not require any indemnified Party to initiate, engage in or threaten litigation with any of its insurance carriers.
          (ii) No Party shall, after the Final Settlement Date, make any Claim for indemnification if and to the extent the Losses with respect to such Claim were fully accounted for in the determination of the Final Adjustment Amount or the Final Closing Indebtedness.
          (c) Except for (i) equitable relief, including, without limitation, injunctive relief or specific performance, to which either Party hereto may be entitled pursuant to other Sections of this Agreement, (ii) any Claims pursuant to Section 2.2 or Section 2.3 and (iii) Claims of fraud, intentional misrepresentation or willful breach of this Agreement, the indemnification provided in this Article IX and Section 10.3 shall be the sole and exclusive remedy of the Parties for monetary damages for any breach of any representation, warranty or covenant contained in this Agreement. Notwithstanding the foregoing, prior to the Closing or in the event of the termination of this Agreement in accordance with Article XI, each Party shall have the right to bring an action to enforce, or recover Losses from, the other Party for breaches of representations, warranties and covenants contained in this Agreement.
          (d) Notwithstanding anything to the contrary in this Agreement, Losses indemnifiable under this Article IX hereof shall expressly exclude punitive damages, except for any such Losses arising out of Third Party Claims (which shall be indemnifiable by the indemnifying Party for all such damages).
          (e) Notwithstanding anything to the contrary herein, Seller shall not be obligated to indemnify, defend and hold harmless the Buyer Indemnified Parties from and against any Losses incurred, suffered or sustained by any Buyer Indemnified Party in connection with, arising out of or resulting from any breach of the representations or warranties made by Seller in Section 4.15 where the matter giving rise to such Losses is discovered as a result of any Buyer Indemnified Parties conducting sampling and analysis of soil or groundwater at any Company Real Property after the Closing Date, except to the extent such sampling is: (i) required by Environmental Laws, including a permit issued pursuant to Environmental Laws; (ii) required by a Governmental Order; (iii) reasonably necessary to investigate identified conditions that indicate an imminent or substantial endangerment to health or the environment; (iv) reasonable to defend against or otherwise respond to a Third Party Claim; (v) with respect to Leased Real Property, necessary to comply with the requirements of the lease agreement pertaining to such Leased Real Property; (vi) requested in writing by a lender or prospective purchaser in connection with a sale, lease, financing or mortgage involving any Company Real Property; or (vii) conducted in connection with proposed construction or expansion at any the Company Real Property, to the extent such sampling is consistent with industry practice, provided, that for the avoidance of doubt, the indemnification of any Buyer Indemnified Parties shall not be limited by any Buyer Indemnified Party conducting sampling or analysis of any drinking water or production water wells that may exist on the Closing Date at any Company Real Property, or of any wastewater discharges at any Company Real Property, or of any indoor or outdoor air at any Company Real Property.

64


 

ARTICLE X.
TAX MATTERS
10.1   Preparation of Tax Returns.
          (a) Seller shall, at its own expense, prepare and timely file all Tax Returns of or including the Company for any Pre-Closing Taxable Period or Straddle Period required to be filed after the Closing Date which Tax Returns also include Seller or any other Subsidiary thereof (such Tax Returns, “Seller Group Returns”) and shall timely pay any Taxes due in respect of such Seller Group Returns. Such Seller Group Returns shall be prepared consistent with past practice, except as otherwise required by Law. Solely as relates to the Company, a copy of each such Seller Group Return shall be delivered to Buyer at least 5 Business Days prior to the filing of such Seller Group Return for Buyer’s review and reasonable comment.
          (b) Buyer shall, at its own expense, prepare consistently with past practice and timely file all other Tax Returns of or relating to the Company for any Pre-Closing Taxable Period or Straddle Period required to be filed after the Closing Date (such Tax Returns, “Separate Company Returns”) and shall timely pay any Taxes due in respect of such Separate Company Returns, subject to Buyer’s indemnification rights under Section 9.2 hereof. A copy of each such Separate Company Return shall be delivered to Seller at least 15 days prior to the due date of such Separate Company Return for Seller’s review and approval (which approval shall not be unreasonably withheld, conditioned or delayed), and all reasonable comments of Seller shall be reflected on such Separate Company Returns prior to filing.
          (c) Neither Buyer nor any of its Affiliates shall (or shall cause or permit the Company or any of its Subsidiaries to) file, amend, refile or otherwise modify any Tax Return relating in whole or in part to the Company with respect to any Pre-Closing Taxable Period (or with respect to any Straddle Period) without the prior written consent of Seller, which consent shall not be unreasonably withheld.
          (d) If and to the extent not fully accounted for in the determination of the Final Adjustment Amount, Seller shall be entitled to the amount of any refund or credit of Pre-Closing Taxes, which refund or credit is actually realized by Buyer or its Subsidiaries (including the Company) after the Closing, net of any Tax cost to Buyer and its Subsidiaries as a result of the receipt of such refund or credit. Buyer shall pay, or cause to be paid, to Seller any amount to which Seller is entitled pursuant to the prior sentence within two Business Days of the receipt or recognition of the applicable refund or credit by Buyer or its Subsidiaries. To the extent requested by Seller, Buyer will reasonably cooperate with Seller in obtaining such refund or credit, including through the filing of amended Tax Returns for periods ending before or on the Closing Date or refund claims. To the extent such refund or credit is subsequently disallowed or required to be returned to the applicable Tax Authority, Seller agrees to repay the amount of such refund or credit, together with any interest, penalties or other additional amounts imposed by the applicable Governmental Authority, to Buyer.
     10.2 Transfer Taxes. All sales, use, transfer, stamp, registration, documentary, excise, real property transfer, or similar Taxes incurred as a result of the transactions contemplated by this Agreement shall be borne 50% by Buyer and 50% by Seller.

65


 

     10.3 Section 338(h)(10) Election.
          (a) Upon Buyer’s request, Seller and Buyer shall join in making a timely and irrevocable election under Code §338(h)(10) (and any corresponding elections under state Tax Law) (collectively, the “Section 338(h)(10) Election”) with respect to the purchase and sale of the Shares of Company. Buyer and Seller shall cooperate with each other and take all actions necessary and appropriate (including filing such additional forms, Tax Returns, elections, schedules and other documents as may be required) to effect and preserve the Section 338 Election in accordance with the provisions of Treasury Regulation Section 1.338(h)(10)-1.
          (b) Within one hundred twenty (120) calendar days after the Closing, Buyer shall prepare a determination of the Aggregate Deemed Sales Price (“ADSP”) (as defined in the applicable Treasury Regulations under Section 338) and a proposed allocation of the ADSP among the assets of the Company (the “Proposed Allocation”) and shall deliver the Proposed Allocation to Seller, together with a copy of any appraisals on which the Proposed Allocation is based. Buyer and Seller shall consult in good faith with regard to the determination of the ADSP and the Proposed Allocation and shall agree on a final allocation (as finally agreed, the “Final Allocation”). As soon as practicable after determination of the Final Allocation, Buyer shall prepare consistently therewith Internal Revenue Service Form 8883 and any similar forms required by applicable state and local Tax Laws (collectively, the “Section 338 Allocation Forms”), and promptly deliver copies of the Section 338 Allocation Forms to Seller for Seller’s review and approval.
          (c) Buyer, the Company and Seller shall file all Tax Returns (including, but not limited to, the Section 338 Election Forms and the Section 338 Allocation Forms) consistent with the Final Allocation.
          (d) Each Party shall bear its own costs and expenses of preparing the Section 338 Election Forms, the Proposed and Final Allocations and the Section 338 Allocation Forms and the calculation of Increased Taxes.
     10.4 Cooperation; Taxes. Buyer and Seller agree to furnish or cause to be furnished to the other, upon request, as promptly as practicable, such information and assistance relating to Taxes, including, without limitation, access to books and records, as is reasonably necessary for the filing of all Tax Returns, the making of any election relating to Taxes, the preparation for any audit by any taxing authority and the prosecution or defense of any Claim, suit or proceeding relating to any Tax. Each of Buyer and Seller shall retain all books and records with respect to Taxes for a period of at least seven (7) years following the Closing Date.
     10.5 Tax Treatment of Indemnification Payments. Any indemnification payments made pursuant to Article 9 or Section 10.3 shall be treated as adjustments to the Purchase Price for Tax purposes.
     10.6 Tax Claims. Notwithstanding anything in this Agreement to the contrary, Seller shall have sole control of the conduct and defense of any audits, disputes, proceedings and Claims involving a Governmental Authority with respect to Pre-Closing Taxes (a “Tax Claim”), provided, however, that Seller shall (i) keep Buyer reasonably informed of material

66


 

developments of the progress of such Tax Claim and (ii) shall not settle or compromise such Tax Claim without the prior written consent of Buyer, not to be unreasonably withheld, in each of (i) and (ii) to the extent such Tax Claim relates to a Straddle Period or the resolution of such Tax Claim could reasonably be expected to materially and adversely affect the liability of Buyer or its Affiliates for Taxes (taking into account Seller’s indemnification obligations hereunder). In the event of any conflict between this Article X and the provisions of Article IX, the provisions of this Article X shall control.
ARTICLE XI.
MISCELLANEOUS
     11.1 Termination.
          (a) This Agreement may be terminated at any time prior to Closing:
          (i) By mutual written consent of Buyer and Seller;
          (ii) By Buyer or Seller if the Closing shall not have occurred on or before October 31, 2010; provided, however, that this provision shall not be available to either Party if such Party’s action or failure to fulfill any obligation under this Agreement has been a proximate cause of, or resulted in, the failure of the Closing to have occurred by such date;
          (iii) By Buyer if there is a breach of any representation or warranty of Seller set forth in Article IV hereof or any covenant or agreement to be complied with or performed by Seller pursuant to the terms of this Agreement where such breach results or would if uncured result, individually or in the aggregate together with all such other breaches by Seller, in the failure of a condition set forth in Article VIII to be satisfied; provided, however, that with respect to the applicable breach, Buyer may not terminate this Agreement prior to the Closing Date if Seller has fully cured such breach within 10 Business Days after the receipt of written notice from Buyer of such failure;
          (iv) By Seller if there is a breach of any representation or warranty of Buyer set forth in Article V hereof or of any covenant or agreement to be complied with or performed by Buyer pursuant to the terms of this Agreement where such breach results or would if uncured result, individually or in the aggregate together with all such other breaches by Buyer, in the failure of a condition set forth in Article VII to be satisfied; provided, however, that with respect to the applicable breach, Seller may not terminate this Agreement prior to the Closing Date if Buyer has fully cured such breach within 10 Business Days after the receipt of written notice from Seller of such failure; or
          (v) by either Party by giving notice to the other Party if any Governmental Authority shall have issued an order, decree or ruling or taken any other action permanently restraining, enjoining or otherwise prohibiting the consummation of any of the transactions contemplated by this Agreement, and such order, decree, ruling or other action shall not be subject to appeal or shall have become final and unappealable.

67


 

          (b) In the event of termination of this Agreement, no Party hereto shall have any Liability under this Agreement to any other Party hereto (or any of its Affiliates, directors, trustees, executors, officers, employees, agents or representatives), except for fraud or any breach of this Agreement occurring prior to the termination of this Agreement. Upon any such termination, subject to Section 6.5, each Party will redeliver or destroy (at such Party’s option) all documents, work papers and other material of any other Party relating to the transactions contemplated hereby, whether so obtained before or after the execution hereof, to the Party furnishing the same, provided that each Party (i) may retain any such information contained in an archived computer system backup in accordance with such Party’s security and/or disaster recovery procedures and (ii) may retains copies of any such information prepared for archival or record retention purposes, where in each case, such information will remain subject to the provisions of Section 6.5. The provisions of Section 6.5 and this Article XI shall continue in full force and effect notwithstanding any termination of this Agreement or any provision hereof to the contrary.
     11.2 Assignment; Successors and Assigns; No Third Party Rights.
          (a) Neither this Agreement nor any of the rights or obligations hereunder may be assigned by any Party (by Contract, operation of Law or otherwise) without the prior written consent of the other Party; provided, that Buyer may, without the prior written consent of Seller, assign any or all of its rights and obligations under this Agreement to one or more of its Affiliates, but no such assignment shall relieve Buyer of its obligations hereunder, and any Party may assign any or all of their respective rights or obligations to any third party who subsequently purchases all or substantially all of the equity or Assets of such Party, subject, in the case of Buyer, to its obligations pursuant to Section 2.3 of this Agreement. Notwithstanding anything else herein to the contrary, it is expressly agreed that the express assumption by the receiving, acquiring, leasing, surviving or successor Person(s) (on a joint and several basis with the relevant Party hereto) of all of the obligations of any Party hereto shall be a condition precedent to the transfer, sale, lease, assignment or other disposition of all or a substantial portion of the business, operations or Assets (including on a consolidated basis with its Subsidiaries) of such party, by way of asset sale, equity sale, merger, consolidation, liquidation, dissolution, recapitalization, operation of Law or otherwise, and that further such assumption shall be deemed to occur automatically to the maximum extent permitted by applicable Law.
          (b) Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and permitted assigns. Except as expressly provided in Article IX, nothing in this Agreement, express or implied, is intended to or shall confer upon any Person other than the parties to this Agreement and their successors and permitted assigns any rights, benefits or remedies of any nature whatsoever under, or by reason of, this Agreement. No third party is entitled to rely on any of the representations, warranties and agreements contained in this Agreement. Buyer and Seller assume no liability to any third party because of any reliance on the representations, warranties and agreements of Buyer or Seller contained in this Agreement.
          (c) Buyer hereby accepts each indemnity under Section 9.2 in favor of each of the other Buyer Indemnified Parties, as agent and trustee of such indemnified party, and Buyer may enforce such indemnities on behalf of that indemnified party. Seller agrees that it

68


 

accepts each indemnity under Section 9.2 in favor of each of the other Seller Indemnified Parties, as agent and trustee of such indemnified party, and Seller may enforce such indemnities on behalf of that indemnified party.
     11.3 Specific Performance. Each Party acknowledges and agrees that the Parties would be damaged irreparably in the event any provision of this Agreement is not performed in accordance with its specific terms or is otherwise breached, so that, in addition to any other remedy that a Party may have under law or equity, each Party shall be entitled to injunctive relief to prevent breaches of the provisions of this Agreement and to enforce specifically this Agreement and the terms and provisions hereof, including the Closing. Each of the Parties hereto hereby waives (i) any defense that a remedy at law would be adequate in any action for specific performance and (ii) any requirement under any applicable law to post a bond or other security as a prerequisite to obtaining equitable relief.
     11.4 Notices. All notices, requests, demands and other communications which are required or may be given under this Agreement shall be in writing and shall be deemed to have been duly given (a) when received if personally delivered, (b) when transmitted if transmitted by telecopy, electronic mail or other digital transmission, (c) the day after it is sent, if sent for next day delivery to a domestic address by recognized overnight delivery service and (d) upon receipt, if sent by certified or registered mail, return receipt requested. In each case any such notice, request, demand or other communication shall be sent to:
          If to Seller, to:
Thoratec Corporation
6035 Stoneridge Drive
Pleasanton, CA 94588
Attention: David Lehman, General Counsel
Facsimile: (925) 734-4043
Email: david.lehman@thoratec.com
          with copies (which shall not constitute notice) to:
Latham & Watkins LLP
885 Third Avenue
New York, New York 10022
Attention: Charles K. Ruck, Esq., M. Adel Aslani-Far, Esq.
Facsimile: (212) 751-4864
Email: [email protected], [email protected]
          If to Buyer, to:
Radiometer America Inc.
c/o Danaher Corporation
2099 Pennsylvania Avenue, 12th Floor

69


 

Washington, D.C. 20006-1813
Attention: Attila Bodi
Facsimile: (202) 828-0850
          with a copy (which shall not constitute notice) to:
Kirkland & Ellis LLP
601 Lexington Avenue
New York, NY 10022
Attention: Daniel E. Wolf
Facsimile: (212) 446-6460
Email: [email protected]
or to such other place and with such other copies as either Party may designate as to itself by written notice to the other.
     11.5 Governing Law. THIS AGREEMENT, AND ANY CLAIM, DEMAND, ACTION OR CAUSE OF ACTION (I) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR (II) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREBY, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE, SHALL BE CONSTRUED, INTERPRETED AND THE RIGHTS OF THE PARTIES DETERMINED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK (WITHOUT REFERENCE TO THE CHOICE OF LAW PROVISIONS THAT WOULD RESULT IN THE APPLICATION OF ANY LAW OTHER THAN THE LAWS OF THE STATE OF NEW YORK).
     11.6 Entire Agreement; Amendments and Waivers. This Agreement (together with the Disclosure Schedules) constitutes the entire agreement among the Parties pertaining to the subject matter hereof and thereof and supersede all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties, including, without limitation, the Confidentiality Agreement (except any provisions of the Confidentiality Agreement relating to the non-solicitation obligations of Buyer). This Agreement may not be amended except by an instrument in writing signed on behalf of each of the Parties hereto. No amendment, supplement, modification or waiver of this Agreement shall be binding unless executed in writing by each Party hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar), nor shall such waiver constitute a continuing waiver unless otherwise expressly provided.
     11.7 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall constitute one and the same instrument, binding upon the Parties hereto. The execution of this Agreement by any of the Parties may be evidenced by way of a facsimile transmission of such Party’s signature, a photocopy of such facsimile transmission or other electronic means, and such facsimile or other electronic signature shall be deemed to constitute the original signature of such Party hereto.

70


 

     11.8 Expenses. Except as otherwise specified in this Agreement, each Party hereto shall pay its own legal, accounting, out-of-pocket and other expenses in connection with, arising out of or incident to this Agreement and the transactions contemplated hereby, including, without limitation, any action taken by such Party in preparation for carrying this Agreement into effect.
     11.9 Severability. In the event that any one or more of the provisions contained in this Agreement or in any other instrument referred to herein, shall, for any reason, be held to be invalid, illegal or unenforceable in any respect, then to the maximum extent permitted by Law, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement or any other such instrument.
     11.10 Titles; Gender; Certain Interpretive Matters. The titles, captions or headings of the Articles and Sections herein, and the use of a particular gender, are for convenience of reference only and are not intended to be a part of or to affect or restrict the meaning or interpretation of this Agreement. Any of such terms, unless the context otherwise requires, may be used in the singular or plural, depending upon the reference. All references in this Agreement to Dollars or “$” shall mean U.S. Dollars. The term “this Agreement” means this Stock Purchase Agreement together with all annexes, Disclosure Schedules and exhibits hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. The use in this Agreement of the term “including” means “including, without limitation.” The words “herein,” “hereof,” “hereunder” and other words of similar import refer to this Agreement as a whole, including the annexes, Disclosure Schedules and exhibits hereto, and not to any particular section, subsection, paragraph, subparagraph or clause contained in this Agreement. Where specific language is used to clarify by example a general statement contained herein, such specific language shall not be deemed to modify, limit or restrict in any manner the construction of the general statement to which it relates. To the extent that this Agreement requires the Company to take or omit to take any action prior to Closing, such agreement and obligations includes the obligation of Seller to cause the Company to take or omit to take such actions. In the event an ambiguity or question of intent arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.
     11.11 Disclosure Schedules; Construction of Certain Provisions. No exceptions to any representations or warranties disclosed in one particular section of the Disclosure Schedules shall constitute an exception to any other representations or warranties made in Article IV or Article V of this Agreement unless the exception is disclosed as provided herein on each such other applicable section of the Disclosure Schedules or cross-referenced in such other applicable section of the Disclosure Schedules or unless the applicability of such exception to another section of the Disclosure Schedules is reasonably apparent on its face. It is understood and agreed that the specification of any dollar amount in the representations and warranties contained in this Agreement or the inclusion of any specific item in the Disclosure Schedules is not intended to imply that such amounts or higher or lower amounts, or the items so included or other items, are or are not material, and no Party shall use the fact of the setting of such amounts or the fact of the inclusion of any such item in the Disclosure Schedules in any dispute or controversy between the Parties as to whether any obligation, item or matter not described herein or included in a Disclosure Schedule is or is not material for purposes of this Agreement. No parol evidence of any nature shall be used in the construction or interpretation of this Agreement.

71


 

     11.12 Service of Process, Consent to Jurisdiction; WAIVER OF JURY TRIAL.
          (a) Each Party hereto irrevocably consents to the service of any process, pleading, notices or other papers by the mailing of copies thereof by registered, certified or first class mail, postage prepaid, to such Party at such Party’s address set forth herein, or by any other method provided or permitted under New York law.
          (b) Except as set forth in Section 2.2, 2.3 and 6.8, any Claim, demand, Action or cause of action (i) arising out of or relating to this Agreement or (ii) in any way connected with or related or incidental to the dealings of the Parties hereto in respect of this Agreement or any of the transactions contemplated hereby, in each case whether now existing or hereafter arising, and whether in contract, tort, equity or otherwise, shall be instituted exclusively in the federal court for the Southern District of New York, or, if such court does not take or have jurisdiction over such Claim, in any New York state court in the county of New York having jurisdiction over such Claim, and each Party hereto agrees not to assert, by way of motion, as a defense or otherwise, in any such Claim, that it is not subject personally to the jurisdiction of any such court, that the Claim is brought in an inconvenient forum, that the venue of the Claim is improper or that this Agreement or the subject matter hereof may not be enforced in or by any such court. Each Party hereto further irrevocably submits to the jurisdiction of any such court in any such Claim.
          (c) EACH PARTY TO THIS AGREEMENT HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (I) ARISING UNDER THIS AGREEMENT OR (II) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS AGREEMENT OR ANY OF THE TRANSACTIONS RELATED HERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. EACH PARTY TO THIS AGREEMENT HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION WILL BE DECIDED BY TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.
     11.13 Independence of Agreements, Covenants, Representations and Warranties. All agreements and covenants hereunder shall be given independent effect so that if a certain action or condition constitutes a default under a certain agreement or covenant, the fact that such action or condition is permitted by another agreement or covenant shall not affect the occurrence of such default. In addition, all representations and warranties hereunder shall be given independent effect so that if a particular representation or warranty proves to be incorrect or is breached, the fact that another representation or warranty concerning the same or similar subject matter is correct or is not breached will not affect the incorrectness of or a breach of a representation and warranty hereunder.

72


 

     11.14 DHR Guaranty.
          (a) From the date hereof until the Closing, Danaher Corporation (“DHR”) hereby irrevocably and unconditionally guarantees to Seller the punctual and full payment in cash, when due from Buyer, of all amounts due to Seller under this Agreement and the performance of all obligations of Buyer under this Agreement. DHR shall make any payments required of it hereunder specifically in accordance with the applicable provisions of this Agreement, as if such payments were being made by Buyer to Seller. The guaranty described in this Section 11.14(a) (i) shall terminate at the Closing and (ii) is a primary guaranty of performance and not just of collection.
          (b) If the Closing occurs, from and after the Closing, DHR hereby irrevocably and unconditionally guarantees to Seller the punctual and full payment in cash, when due from Buyer, of all Earnout Amounts (if any) due to Seller under Section 2.3. To the extent payment is not made by Buyer, DHR shall make any payments required of it under Section 2.3 specifically in accordance with the applicable provisions of Section 2.3, as if such payments were being made by Buyer to Seller. The guaranty described in this Section 11.14(b) shall terminate when all Earnout Amounts (if any) have been fully paid. The guaranty described in this Section 11.14(b), together with the guaranty described in Section 11.14(a), shall be herein referred to as the “Guaranty.”
          (c) DHR represents that, directly or through one or more wholly-owned Subsidiaries, it owns 100% of the outstanding Equity Interests of Buyer.
          (d) DHR hereby waives (i) notice of acceptance of the Guaranty; (ii) presentment and demand concerning the Liabilities of DHR; and (iii) any right to require that any Action be brought against Buyer or any other Person, or to require that Seller seek enforcement of any performance against Buyer or any other Person prior to any Action against DHR under the terms hereof.
          (e) Except as to applicable statutes of limitation, no delay of Seller in the exercise of, or failure to exercise, any rights under the Guaranty shall operate as a waiver of such rights, a waiver of any other rights, or a release of DHR from any obligations hereunder.
          (f) DHR consents to the renewal, compromise, extension, acceleration or other changes in the time of payment of, or other changes in the terms of the obligations subject to, the Guaranty or any part thereof or any changes or modifications to the terms of the Guaranty, in each case, to the extent agreed in writing by Buyer, in accordance with this Agreement.
          (g) DHR agrees that the Guaranty shall continue to be effective or shall be reinstated, as the case may be, if all or any part of any payment made thereunder is at any time avoided or rescinded or must otherwise be restored or repaid as a result of the bankruptcy of Buyer or DHR, or otherwise avoided or recovered directly or indirectly from Seller as a preference, fraudulent transfer or otherwise, irrespective of any notice of revocation given by Buyer or DHR prior to such avoidance or recovery.

73


 

          IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed on their respective behalf, by their respective officers thereunto duly authorized, all as of the day and year first above written.
         
  Seller:

THORATEC CORPORATION

 
 
  By:   /s/ Gerhard F. Burbach    
  Name:   Gerhard F. Burbach   
  Title:   President and Chief Executive Officer   
 
  Buyer:

RADIOMETER AMERICA INC.

 
 
  By:   /s/ James F. O’Reilly    
  Name:   James F. O’Reilly   
  Title:   Vice President and Secretary   
 
  DHR:

DANAHER CORPORATION

(solely for purposes of Section 11.14 hereof)
 
 
  By:   /s/ James F. O’Reilly    
  Name:   James F. O’Reilly   
  Title:   Secretary and Associate General Counsel